## **WEST Search History**

Hide Items Restore Clear Cancel

DATE: Monday, February 09, 2004


Hide? Set Name Query Hit C			Hit Count	
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ				
	L24	L23 AND amyloid	. 13	
	L23	Ab5 OR Ab12 OR Ab13-28 OR Ab40 OR Ab42	1312	
	L22	L21 AND Ab42	3	
	L21	L20 AND adjuvant	1637	
	L20	L19 AND Alzheimer	4868	
	L19	amyloid	6773	
	L18	L17 AND adjuvant	79	
	L17	L16 AND antibody	96	
	L16	L15 AND amyloid	97	
	L15	424/184.1,185.1.CCLS.	3097	
	L14	L13 AND Ab42	1	
	L13	L12 AND adjuvant	730	
	L12	L10 AND Ab	1371	
	L11	L10 AND abeta	2	
	L10	514/1,2.CCLS.	6597	
DB=USPT; PLUR=YES; OP=ADJ				
	L9	Schenk-D.IN.	0	
	L8	Schenk-Dale-B.IN.	12	
	L7	Schenk-Dale IN.	2	
	L6	Schenk.IN.	732	
	DB=PC	GPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES	S; OP=ADJ	
	L5	Schenk-D.IN.	6	
	L4	Schenk-D-B.IN.	16	
	L3	Schenk-Dale.IN.	3	
	L2	Schenk-Dale-B.IN.	21	
	L1	(Schenk.IN.)	2759	

END OF SEARCH HISTORY

Related Articles, Links









OMIM PMC. Book Journals Protein Structure PubMed Nucleotide Genome Entrez Search PubMed for amyloid AND adjuvant Go Clear Clipboard Details Limits Preview/Index History About Entrez ▼ Show: 500 ▼ Sort Send to Display Summary One page. Items 1-213 of 213 Text Version 1: Kawabe S, Abe T, Kawamura H, Gejyo F, Abo T. Related Articles, Links Entrez PubMed Generation of B220low B cells and production of autoantibodies in mice Overview with experimental amyloidosis: association of primordial T cells with this Help | FAQ Tutorial phenomenon. New/Noteworthy Clin Exp Immunol. 2004 Feb;135(2):200-8. E-Utilities PMID: 14738446 [PubMed - in process] 2: Lima AC, Louzada PR, De Mello FG, Ferreira ST. Related Articles, Links PubMed Services Journals Database Neuroprotection against Abeta and glutamate toxicity by melatonin: are MeSH Database Single Citation Matcher GABA receptors involved? Batch Citation Matcher Neurotox Res. 2003;5(5):323-7. Clinical Queries PMID: 14715451 [PubMed - indexed for MEDLINE] LinkOut 1 3: Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba Cubby Related Articles, Links D. He W. Related Resources A novel recombinant adeno-associated virus vaccine reduces behavioral Order Documents impairment and beta-amyloid plagues in a mouse model of Alzheimer's **NLM Gateway** TOXNET Consumer Health Neurobiol Dis. 2003 Dec;14(3):365-79. Clinical Alerts PMID: 14678754 [PubMed - in process] ClinicalTrials.gov PubMed Central Related Articles, Links 4: Cheng SY, Trombetta LD. The induction of amyloid precursor protein and alpha-synuclein in rat Privacy Policy hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione. Toxicol Lett. 2004 Jan 15;146(2):139-49. PMID: 14643966 [PubMed - indexed for MEDLINE] 5: Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan Related Articles, Links D, Tian W, Sadzikaya N, Ross TM, Head E, Cribbs DH, Agadianyan MG. Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol. 2003 Dec;33(12):3232-41. PMID: 14635031 [PubMed - indexed for MEDLINE] 6: Kuroiwa M. Aoki K. Izumiyama N. Related Articles, Links Histological study of experimental murine AA amyloidosis. J Electron Microsc (Tokyo). 2003;52(4):407-13. PMID: 14599103 [PubMed - indexed for MEDLINE] Related Articles, Links 7: Tarkowski E. Cytokines in dementias. Curr Drug Targets Inflamm Allergy. 2002 Jun;1(2):193-200. Review.


PMID: 14561200 [PubMed - indexed for MEDLINE]

8: Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R,

Offen D.








does not produce aversive consequences.

Peptides. 2002 May;23(5):985-8.

PMID: 12084531 [PubMed - indexed for MEDLINE] 35: Gagnon RF, Thirtweil M, Arzoumanian A, Mehio A. Related Articles, Links Systemic amyloidosis involving the diaphragm and acute massive hydrothorax during peritoneal dialysis. Clin Nephrol. 2002 Jun;57(6):474-9. PMID: 12078953 [PubMed - indexed for MEDLINE] 36: Thorn CF, Whitehead AS. Related Articles, Links Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J Immunol. 2002 Jul 1;169(1):399-406. PMID: 12077270 [PubMed - indexed for MEDLINE] 37: Shen YX, Xu SY, Wei W, Wang XL, Wang H, Sun X. Related Articles, Links Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta-peptide 25-35. J Pineal Res. 2002 Apr;32(3):163-7. PMID: 12074099 [PubMed - indexed for MEDLINE] 138: Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Related Articles, Links Poeggeler B, Dubocovich M, Bick R, Perry G, Cruz-Sanchez F. Smith MA. The neuroprotective activities of melatonin against the Alzheimer beta-= protein are not mediated by melatonin membrane receptors. J Pineal Res. 2002 Apr;32(3):135-42. PMID: 12074096 [PubMed - indexed for MEDLINE] 39: Shen YX, Xu SY, Wei W, Sun XX, Liu LH, Yang J, Dong C. Related Articles, Links The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J Pineal Res. 2002 Mar;32(2):85-9. PMID: 12071472 [PubMed - indexed for MEDLINE] 40: Green KN, Boyle JP, Peers C. Related Articles, Links Hypoxia potentiates exocytosis and Ca2+ channels in PC12 cells via increased amyloid beta peptide formation and reactive oxygen species generation. J Physiol. 2002 Jun 15;541(Pt 3):1013-23. PMID: 12068059 [PubMed - indexed for MEDLINE] Related Articles, Links 41: Green KN, Peers C. Divergent pathways account for two distinct effects of amyloid beta peptides on exocytosis and Ca(2+) currents: involvement of ROS and NFkappaB. J Neurochem. 2002 Jun;81(5):1043-51. PMID: 12065617 [PubMed - indexed for MEDLINE] 42: Blanchard BJ, Thomas VL, Ingram VM. Related Articles, Links Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem Biophys Res Commun. 2002 May 17;293(4):1197-203. PMID: 12054502 [PubMed - indexed for MEDLINE] 13: Olivieri G, Otten U, Meier F, Baysang G, Dimitriades-Schmutz B, Related Articles, Links

Oxidative stress modulates tyrosine kinase receptor A and p75 receptor

Muller-Spahn F, Savaskan E



induced by amyloid beta-peptide 25-35.

Acta Pharmacol Sin. 2002 Jan;23(1):71-6. PMID: 11860741 [PubMed - indexed for MEDLINE] 53: Frenkel D. Solomon B. Related Articles, Links Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE] 54: Lemere CA, Maron R, Selkoe DJ, Weiner HL. Related Articles, Links Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001 Nov;20(11):705-11. PMID: 11788048 [PubMed - indexed for MEDLINE] 55: Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Related Articles, Links Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002 Jan; 122(1):94-105. PMID: 11781285 [PubMed - indexed for MEDLINE] 56: Shen YX, Wei W, Yang J, Liu C, Dong C, Xu SY. Related Articles, Links Improvement of melatonin to the learning and memory impairment induced by amyloid beta-peptide 25 - 35 in elder rats. Acta Pharmacol Sin. 2001 Sep;22(9):797-803. PMID: 11749859 [PubMed - indexed for MEDLINE] 57: Skribanek Z. Balaspiri L. Mak M. Related Articles, Links Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom. 2001 Nov;36(11):1226-9. PMID: 11747119 [PubMed - indexed for MEDLINE] 58: Poeggeler B, Miravalle L, Zagorski MG, Wisniewski T, Chyan YJ, Related Articles, Links Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J. Pappolla MA. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001 Dec 11;40(49):14995-5001. PMID: 11732920 [PubMed - indexed for MEDLINE] 59: Poduslo JF, Curran GL. Related Articles, Links Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 2001 Oct 29;12(15):3197-200. PMID: 11711855 [PubMed - indexed for MEDLINE] 60: Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, Related Articles, Links Brockhaus M. Muller-Spahn F. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res. 2001 Nov;31(4):320-5. PMID: 11703561 [PubMed - indexed for MEDLINE] Related Articles, Links 61: Van Nostrand WE, Melchor JP.

Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells.

Amyloid. 2001 Jul;8 Suppl 1:20-7.

PMID: 11676286 [PubMed - indexed for MEDLINE] 62: Benveniste EN, Nguyen VT, O'Keefe GM. Related Articles, Links Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):381-91. Review. PMID: 11578773 [PubMed - indexed for MEDLINE] Related Articles, Links 63: Thatte U. AN-1792 (Elan). Curr Opin Investig Drugs. 2001 May;2(5):663-7. Review. PMID: 11569944 [PubMed - indexed for MEDLINE] Related Articles, Links 64: Kourie JI, Henry CL, Farrelly P. Diversity of amyloid beta protein fragment [1-40]-formed channels. Cell Mol Neurobiol. 2001 Jun;21(3):255-84. PMID: 11569537 [PubMed - indexed for MEDLINE] [65: Vigneswaran N, Fernandes R, Rodu B, Baughman RA, Siegal GP. Related Articles, Links Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings. Pathol Res Pract. 2001;197(8):569-76. PMID: 11518051 [PubMed - indexed for MEDLINE] [ 66: Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC, Related Articles, Links Kohen R, Shohami E, Huo YS, Hardeland R, Reiter RJ. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001 Oct;15(12):2294-6. Epub 2001 Aug 17. PMID: 11511530 [PubMed - indexed for MEDLINE] 67: Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Related Articles, Links Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67. PMID: 11487050 [PubMed - indexed for MEDLINE] 68: Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Related Articles, Links Herer P, Lavie P. Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol Int. 2001 May; 18(3):513-24. PMID: 11475420 [PubMed - indexed for MEDLINE] [ 69: Clapp-Lilly KL, Smith MA, Perry G, Harris PL, Zhu X, Duffy LK. Related Articles, Links Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. Neuroreport. 2001 May 8;12(6):1277-80. PMID: 11338206 [PubMed - indexed for MEDLINE] 70: Clapp-Lilly KL, Smith MA, Perry G, Duffy LK. Related Articles, Links Melatonin reduces interleukin secretion in amyloid-beta stressed mouse

Related Articles, Links

brain slices.


71: Schmidt U, Wagner H, Miethke T.

Chem Biol Interact. 2001 Mar 14;134(1):101-7. PMID: 11248225 [PubMed - indexed for MEDLINE]

Related Articles, Links


	Cell Microbiol. 1999 Jul;1(1):61-7. PMID: 11207541 [PubMed - indexed for MEDLINE]	
72:	Boylan MT, Crockard AD, Duddy ME, Armstrong MA, McMillan SA, Hawkins SA.	Related Articles, Links
	Interferon-beta1a administration results in a transient inc amyloid A protein and C-reactive protein: comparison w of inflammation. Immunol Lett. 2001 Jan 15;75(3):191-7. PMID: 11166375 [PubMed - indexed for MEDLINE]	
□ 73:	Bayne CJ, Gerwick L, Fujiki K, Nakao M, Yano T.	Related Articles, Links
	Immune-relevant (including acute phase) genes identified rainbow trout, Oncorhynchus mykiss, by means of supprhybridization.  Dev Comp Immunol. 2001 Apr;25(3):205-17.  PMID: 11164886 [PubMed - indexed for MEDLINE]	d in the livers of ression subtractive
□ 74:	Prapong T, Uemura E, Hsu WH.	Related Articles, Links
	G protein and cAMP-dependent protein kinase mediate a peptide inhibition of neuronal glucose uptake. Exp Neurol. 2001 Jan;167(1):59-64. PMID: 11161593 [PubMed - indexed for MEDLINE]	amyloid beta-
□ 75:	Mold C. Gresham HD, Du Clos TW.	Related Articles, Links
	Serum amyloid P component and C-reactive protein med through murine Fc gamma Rs. J Immunol. 2001 Jan 15;166(2):1200-5. PMID: 11145702 [PubMed - indexed for MEDLINE]	liate phagocytosis
□ 76:	Szczepanik AM, Funes S, Petko W, Ringheim GE.	Related Articles, Links
	IL-4, IL-10 and IL-13 modulate A beta(142)-induced c chemokine production in primary murine microglia and cell line.  J Neuroimmunol. 2001 Feb 1;113(1):49-62.  PMID: 11137576 [PubMed - indexed for MEDLINE]	
□ 77:	Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S.	Related Articles, Links
	Muscarinic agonists reduce tau phosphorylation in non-reGSK-3beta inhibition and in neurons.  J Neural Transm. 2000;107(10):1201-12.  PMID: 11129110 [PubMed - indexed for MEDLINE]	neuronal cells via
□ 78:	Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA	Related Articles, Links
	Neuronal oxidative stress precedes amyloid-beta deposit syndrome. J Neuropathol Exp Neurol. 2000 Nov;59(11):1011-7. PMID: 11089579 [PubMed - indexed for MEDLINE]	ion in Down
<b>□ 79:</b>	Barger SW, Chavis JA, Drew PD.	Related Articles, Links
	Dehydroepiandrosterone inhibits microglial nitric oxide stimulus-specific manner.  J Neurosci Res. 2000 Nov 15;62(4):503-9.  PMID: 11070493 [PubMed - indexed for MEDLINE]	production in a

80: Frenkel D, Katz O, Solomon B.



Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma

		-
	but not in glioma cells. Proc Soc Exp Biol Med. 2000 Apr;223(4):397-402. PMID: 10721010 [PubMed - indexed for MEDLINE]	
□ 90:	Dore S, Bastianetto S, Kar S, Quinon R.	Related Articles, Links
	Protective and rescuing abilities of IGF-I and some puta scavengers against beta-amyloid-inducing toxicity in ne Ann N Y Acad Sci. 1999;890:356-64. PMID: 10668442 [PubMed - indexed for MEDLINE]	
□ 91	Bachurin S, Oxenkrug G, Lermontova N, Afanasiev A, Beznosko B, Vankin G, Shevtzova E, Mukhina T, Serkova T.	Related Articles, Links
	N-acetylserotonin, melatonin and their derivatives improportect against beta-amyloid-induced neurotoxicity.  Ann N Y Acad Sci. 1999;890:155-66.  PMID: 10668422 [PubMed - indexed for MEDLINE]	ove cognition and
□ 92	Brown RC, Cascio C, Papadopoulos V.	Related Articles, Links
	Pathways of neurosteroid biosynthesis in cell lines from regulation of dehydroepiandrosterone formation by oxid beta-amyloid peptide.  J Neurochem. 2000 Feb;74(2):847-59. PMID: 10646538 [PubMed - indexed for MEDLINE]	
□ 93	Svensson AL, Nordberg A.	Related Articles, Links
	Beta-estradiol attenuate amyloid beta-peptide toxicity v receptors. Neuroreport. 1999 Nov 26;10(17):3485-9. PMID: 10619630 [PubMed - indexed for MEDLINE]	ia nicotinic
□ 94	Olivieri G, Brack C, Muller-Spahn F, Stahelin HB, Herrmann M, Renard P, Brockhaus M, Hock C.	Related Articles, Links
	Mercury induces cell cytotoxicity and oxidative stress a amyloid secretion and tau phosphorylation in SHSY5Y cells.  J Neurochem. 2000 Jan;74(1):231-6. PMID: 10617124 [PubMed - indexed for MEDLINE]	
<b>□</b> 95	· Cardounel A, Regelson W, Kalimi M.	Related Articles, Links
	Dehydroepiandrosterone protects hippocampal neurons induced cell death: mechanism of action.  Proc Soc Exp Biol Med. 1999 Nov;222(2):145-9.  PMID: 10564538 [PubMed - indexed for MEDLINE]	against neurotoxin-
□ 96	Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J, LeDoux SP, Wilson GL.	Related Articles, Links
	Alzheimer beta protein mediated oxidative damage of reprevention by melatonin.  J Pineal Res. 1999 Nov;27(4):226-9.  PMID: 10551770 [PubMed - indexed for MEDLINE]	nitochondrial DNA:
<b>5</b> 97	: Yang EY, Guo-Ross SX, Bondy SC.	Related Articles, Links
	The stabilization of ferrous iron by a toxic beta-amyloid an aluminum salt.  Brain Res. 1999 Aug 28;839(2):221-6.  PMID: 10519044 [PubMed - indexed for MEDLINE]	d fragment and by
□ 98	• Mulder H. Jongsma H. Zhang Y. Gebre-Medhin S. Sundler F. Danielsen N.	Related Articles, Links




PMID: 10036585 [PubMed - indexed for MEDLINE] 107: Brusco LI, Marquez M, Cardinali DP. Related Articles, Links Monozygotic twins with Alzheimer's disease treated with melatonin: Case J Pineal Res. 1998 Dec;25(4):260-3. PMID: 9885996 [PubMed - indexed for MEDLINE] 108: Gebre-Medhin S. Mulder H. Zhang Y. Sundler F. Betsholtz C. Related Articles, Links Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice. Brain Res Mol Brain Res. 1998 Dec 10;63(1):180-3. PMID: 9838101 [PubMed - indexed for MEDLINE] 109: Kirkley SA, Cowles J, Pellegrini VD, Harris CM, Boyd AD. Related Articles, Links Blumberg N. Blood transfusion and total joint replacement surgery: T helper 2 (TH2) cytokine secretion and clinical outcome. Transfus Med. 1998 Sep;8(3):195-204. PMID: 9800291 [PubMed - indexed for MEDLINE] Related Articles, Links 110: Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol. 1998 Oct;56(3):359-84. Review. PMID: 9770244 [PubMed - indexed for MEDLINE] 111: Fayad PB, Awad IA. Related Articles, Links Surgery for intracerebral hemorrhage. Neurology. 1998 Sep;51(3 Suppl 3):S69-73. Review. PMID: 9744840 [PubMed - indexed for MEDLINE] 112: Cheshenko VP. Related Articles, Links [Prognostic value of tumor markers in intestinal cancer] Klin Khir. 1998;(4):40. Russian. PMID: 9695522 [PubMed - indexed for MEDLINE] Related Articles, Links 113: Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 1998 Jul 13;799(1):91-6. PMID: 9666089 [PubMed - indexed for MEDLINE] 114: Timoshenko AV, Bovin NV, Shiyan SD, Vakhrushev SY, Andre Related Articles, Links S. Gabius HJ. Modification of the functional activity of neutrophils treated with acute phase response proteins. Biochemistry (Mosc). 1998 May;63(5):546-50. PMID: 9632890 [PubMed - indexed for MEDLINE] 115: Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski Related Articles, Links M. Frangione B, Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem. 1998 Mar 27;273(13):7185-8. PMID: 9516407 [PubMed - indexed for MEDLINE] 116: Daniels WM, van Rensburg SJ, van Zyl JM, Taljaard JJ. Related Articles, Links


Melatonin prevents beta-amyloid-induced lipid peroxidation.


J Pineal Res. 1998 Mar;24(2):78-82.


PMID: 9510431 [PubMed - indexed for MEDLINE]




Hashimoto S, Katou M. Dong Y, Murakami K, Terada S, Inoue










Technetium-99-labelled methylene diphosphonate uptake scans in

Related Articles, Links

	patients with dialysis arthropathy. Nephron. 1990;54(3):202-7. PMID: 2314536 [PubMed - indexed for MEDLINE]	
□ 163:	Shirahama T. Miura K., Ju ST, Kisilevsky R, Gruys E, Cohen AS.	Related Articles, Links
	Amyloid enhancing factor-loaded macrophages in amy formation. Lab Invest. 1990 Jan;62(1):61-8. PMID: 2296158 [PubMed - indexed for MEDLINE]	loid fibril
□ 164:	Rokita H. Shirahama T. Cohen AS, Sipe JD.	Related Articles, Links
	Serum amyloid A gene expression and AA amyloid for SJL/J mice. Br J Exp Pathol. 1989 Jun;70(3):327-35. PMID: 2765389 [PubMed - indexed for MEDLINE]	mation in A/J and
□ 165:	Ueda K, Cole G, Sundsmo M, Katzman R, Saitoh T.	Related Articles, Links
	Decreased adhesiveness of Alzheimer's disease fibroble beta-protein precursor involved? Ann Neurol. 1989 Mar;25(3):246-51. PMID: 2729915 [PubMed - indexed for MEDLINE]	asts: is amyloid
□ 166:	Kimber I, Ward RK, Shepherd CJ, Smith MN, McAdam KP, Raynes JG.	Related Articles, Links
	Acute-phase proteins and the serological evaluation of contact sensitivity in the mouse. Int Arch Allergy Appl Immunol. 1989;89(2-3):149-55. PMID: 2474509 [PubMed - indexed for MEDLINE]	experimental
□ 167:	Hamazaki H.	Related Articles, Links
□ 167:	•	,
	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans.  Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8.	,
	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8. PMID: 3276308 [PubMed - indexed for MEDLINE] Hilgers LA, de Reuver MJ, Vaandrager AR. Ong T. Snippe H,	P component and Related Articles, Links
☐ 168: ☐	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8.  PMID: 3276308 [PubMed - indexed for MEDLINE]  Hilgers LA, de Reuver MJ, Vaandrager AR, Ong T, Snippe H, Willers JM.  Serum amyloid P component induction by immunomod Nat Immun Cell Growth Regul. 1988;7(5-6):328-33.	P component and Related Articles, Links
☐ 168: ☐	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8.  PMID: 3276308 [PubMed - indexed for MEDLINE]  Hilgers LA, de Reuver MJ, Vaandrager AR, Ong T, Snippe H, Willers JM.  Serum amyloid P component induction by immunomod Nat Immun Cell Growth Regul. 1988;7(5-6):328-33.  PMID: 2464762 [PubMed - indexed for MEDLINE]	P component and Related Articles, Links dulators. Related Articles, Links
☐ 168: ☐ 169:	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8. PMID: 3276308 [PubMed - indexed for MEDLINE]  Hilgers LA, de Reuver MJ, Vaandrager AR, Ong T, Snippe H, Willers JM.  Serum amyloid P component induction by immunomod Nat Immun Cell Growth Regul. 1988;7(5-6):328-33. PMID: 2464762 [PubMed - indexed for MEDLINE]  Richard KA, Mortensen RF, Tracey DE.  Cytokines involved in the augmentation of murine naturactivity by pyrimidinones in vivo. J Biol Response Mod. 1987 Dec;6(6):647-63.	P component and Related Articles, Links dulators. Related Articles, Links
☐ 168: ☐ 169:	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8. PMID: 3276308 [PubMed - indexed for MEDLINE]  Hilgers LA, de Reuver MJ, Vaandrager AR, Ong T, Snippe H, Willers JM.  Serum amyloid P component induction by immunomod Nat Immun Cell Growth Regul. 1988;7(5-6):328-33. PMID: 2464762 [PubMed - indexed for MEDLINE]  Richard KA, Mortensen RF, Tracey DE.  Cytokines involved in the augmentation of murine naturactivity by pyrimidinones in vivo. J Biol Response Mod. 1987 Dec;6(6):647-63. PMID: 2453616 [PubMed - indexed for MEDLINE]	Related Articles, Links dulators.  Related Articles, Links aral killer cell  Related Articles, Links
☐ 168: ☐ 169: ☐ 170:	Hamazaki H.  Calcium-mediated hemagglutination by serum amyloid the inhibition by specific glycosaminoglycans. Biochem Biophys Res Commun. 1988 Jan 15;150(1):212-8. PMID: 3276308 [PubMed - indexed for MEDLINE]  Hilgers LA, de Reuver MJ, Vaandrager AR, Ong T, Snippe H, Willers JM.  Serum amyloid P component induction by immunomod Nat Immun Cell Growth Regul. 1988;7(5-6):328-33. PMID: 2464762 [PubMed - indexed for MEDLINE]  Richard KA, Mortensen RF, Tracey DE.  Cytokines involved in the augmentation of murine naturactivity by pyrimidinones in vivo.  J Biol Response Mod. 1987 Dec;6(6):647-63. PMID: 2453616 [PubMed - indexed for MEDLINE]  Hol PR, Snel FW, Draaijer M, Gruys E.  The serum amyloid A stimulating factor (SAASF) in the J Comp Pathol. 1987 Nov;97(6):677-85.	Related Articles, Links dulators.  Related Articles, Links aral killer cell  Related Articles, Links

172: Blumenthal HT, Premachandra BN.



PMID: 6180838 [PubMed - indexed for MEDLINE] 182: Pollak A, Coradello H, Latzka U, Lischka A, Lubec G. Related Articles, Links [Interacting between amyloid P and connective tissue proteins] Wien Klin Wochenschr. 1982 May 28;94(11):291-3. German. PMID: 6812292 [PubMed - indexed for MEDLINE] Related Articles, Links 183: Livni N, Laufer A, Levo Y. Demonstration of amyloid in murine and human secondary amyloidosis by the immunoperoxidase technique. J Pathol. 1980 Dec; 132(4):343-8. PMID: 7003080 [PubMed - indexed for MEDLINE] 184: Miller MW, Shearer GM, McAdam KP. Related Articles, Links Suppression of T cell-mediated cytotoxic responses by spleen cells from mice rendered pre-amyloid by a single injection of complete Freund's adjuvant and Mycobacterium butyricum. J Immunol. 1980 Dec;125(6):2559-64. No abstract available. PMID: 6448899 [PubMed - indexed for MEDLINE] Related Articles, Links 185: Suzuki T, Ishikawa S, Motoyama T, Oboshi S. Suppression and acceleration of experimental amyloidosis in mouse model. Acta Pathol Jpn. 1980 Jul;30(4):557-64. PMID: 7415838 [PubMed - indexed for MEDLINE] 186: Rush DN, Bridges AR, Skinner M, Cohen AS, Lindsay RM. Related Articles, Links The effect of levamisole in experimental murine amyloidosis. J Immunopharmacol. 1980;2(4):553-65. PMID: 7205004 [PubMed - indexed for MEDLINE] 187: Hanai N, Ishihara T, Uchino F, Imada N, Fujihara S, Ikegami J. Related Articles, Links Effects of dimethyl sulfoxide and colchicine on the resorption of experimental amyloid. Virchows Arch A Pathol Anat Histol. 1979;384(1):45-52. PMID: 159544 [PubMed - indexed for MEDLINE] Related Articles, Links 188: Seaman JP, Kieldsberg CR, Linker A. Gelatinous transformation of the bone marrow. Hum Pathol. 1978 Nov;9(6):685-92. PMID: 730150 [PubMed - indexed for MEDLINE] Related Articles, Links 189: Kopolovicz J, Fields M, Laufer A. Effect of papain on experimental amyloidosis. =Experientia. 1978 Apr 15;34(4):524-6. PMID: 639956 [PubMed - indexed for MEDLINE] Related Articles, Links 190: Szekeres L. Orfanos CE. Alterations of the clinically noninvolved skin in patients with malignant melanoma. An electron microscopic study before and after repeated application of BCG. Dermatologica. 1978;156(3):142-54. PMID: 624428 [PubMed - indexed for MEDLINE] 191: Sipe JD, McAdam KP, Uchino F. Related Articles, Links

Biochemical evidence for the biphasic development of experimental

amyloidosis.

Lab Invest. 1978 Jan;38(1):110-4. No abstract available. PMID: 621923 [PubMed - indexed for MEDLINE] Related Articles, Links 192: Mohr W. Wild A. [Morphologic studies on rats with adjuvant disease of long duration] Z Rheumatol. 1976 Jul-Aug;35(7-8):301-11. German. PMID: 961081 [PubMed - indexed for MEDLINE] Related Articles, Links 193: Schechter D, Fields M, Laufer A. The effect of beta aminoproprionitrile (BAPN) on experimental amyloidosis. Br J Exp Pathol. 1975 Oct;56(5):466-70. PMID: 1212427 [PubMed - indexed for MEDLINE] Related Articles, Links 194. Palmoski MJ, Brandt KD. Stimulation of glycosaminoglycan biosynthesis by amyloid fibrils. Biochem J. 1975 Apr; 148(1):145-7. PMID: 125588 [PubMed - indexed for MEDLINE] Related Articles, Links 195: Fields M, Polliack A, Laufer A. Resorption of amyloid and enzymatic studies in amyloidosis. Isr J Med Sci. 1973 Jul;9(7):875-80. No abstract available. PMID: 4200185 [PubMed - indexed for MEDLINE] 196: Polliack A, Laufer A, George R, Fields M. Related Articles, Links The effect of cortisone on the formation and resorption of experimental amyloid. Br J Exp Pathol. 1973 Feb;54(1):6-12. No abstract available. PMID: 4689823 [PubMed - indexed for MEDLINE] Related Articles, Links 197: Fields M, Laufer A, Polliack A. Lysosomal enzyme studies in experimental amyloidosis of mice treated with cortisone. Acta Pathol Microbiol Scand [A]. 1973;236:Suppl 236:15-2. No abstract available. PMID: 4774991 [PubMed - indexed for MEDLINE] Related Articles, Links 198: Rukosuev VS. [Participation of gamma-globulin and specific antibodies in the formation of amyloid] Arkh Patol. 1973;35(11):33-8. Russian. No abstract available. PMID: 4135234 [PubMed - indexed for MEDLINE] 199: Laufer A, Fields M, Polliack A. Related Articles, Links Lysosomal enzymes and their relation to the distribution and resorption of experimental amyloid. Acta Pathol Microbiol Scand [A]. 1972;233:183-8. No abstract available. PMID: 5074630 [PubMed - indexed for MEDLINE] Related Articles, Links 200: Rigdon RH, Schadewald T. Amyloid in the gastrointestinal tract of mice. Tex Rep Biol Med. 1972 Spring;30(1):85-95. No abstract available. PMID: 4114016 [PubMed - indexed for MEDLINE] 201: Glenner GG, Page D, Isersky C, Harada M, Cuatrecasas P, Eanes Related Articles, Links ED, DeLellis RA, Bladen HA, Keiser HR. Murine amyloid fibril protein: isolation, purification and characterization.

J Histochem Cytochem. 1971 Jan;19(1):16-28. No abstract available.

PMID: 5545341 [PubMed - indexed for MEDLINE]

Related Articles, Links

□ 202:	Polliack A, Laufer A, Tal C.	Related Articles, Links
	Studies on the resorption of experimental amyloidosis. Br J Exp Pathol. 1970 Jun;51(3):236-41. No abstract available. PMID: 5429070 [PubMed - indexed for MEDLINE]	
□ 203:	Andreev D, Ditzov S, Dashev G.	Related Articles, Links
	[Diabetes-like vascular lesions in the kidneys of guinea with an insulin-adjuvant mixture] Acta Diabetol Lat. 1970 Mar-Apr;7(2):243-59. Multilingual. No al PMID: 5494805 [PubMed - indexed for MEDLINE]	
□ 204:	DeLellis RA, Sri Ram J, Glenner GG.	Related Articles, Links
	Amyloid. IX. Further kinetic studies on experimental m Int Arch Allergy Appl Immunol. 1970;37(2):175-83. No abstract a PMID: 5411246 [PubMed - indexed for MEDLINE]	
□ 205:	Berenson G, Dalferes ER Jr, Ruiz H, Radhakrishnamurthy B.	Related Articles, Links
	Changes of mucopolysaccharides in the heart involved Am J Cardiol. 1969 Sep;24(3):358-64. No abstract available. PMID: 4185028 [PubMed - indexed for MEDLINE]	by amyloidosis.
□ 206:	Ram JS, DeLellis RA, Glenner GG.	Related Articles, Links
	Amyloid. 8. On strain variability in experimental murin Proc Soc Exp Biol Med. 1969 Feb;130(2):462-4. No abstract avail PMID: 5765280 [PubMed - indexed for MEDLINE]	
<b>207</b> :	Ram JS, DeLellis RA, Glenner GG.	Related Articles, Links
	Amyloid. VII. Kinetics of murine amyloidosis induced type adjuvant. Int Arch Allergy Appl Immunol. 1969;35(3):288-97. No abstract a PMID: 5766066 [PubMed - indexed for MEDLINE]	
<b>208</b> :	Ram JS, Glener GG, DeLellis RA.	Related Articles, Links
	Amyloid. I. Use of Freund's adjuvant in experimental at Proc Soc Exp Biol Med. 1968 Mar;127(3):854-6. No abstract avail PMID: 5651146 [PubMed - indexed for MEDLINE]	
<b>209</b> :	Pennock CA.	Related Articles, Links
	Association of acid mucopolysaccharides with isolated Nature. 1968 Feb 24;217(5130):753-4. No abstract available. PMID: 4230508 [PubMed - indexed for MEDLINE]	amyloid fibrils.
<b>1</b> 210:	Ram JS, DeLellis RA, Glenner GG,	Related Articles, Links
	Amyloid. 3. A method for rapid induction of amyloidos Int Arch Allergy Appl Immunol. 1968;34(2):201-4. No abstract av PMID: 5667376 [PubMed - indexed for MEDLINE]	
□ 211:	Sri Ram J, DeLellis RA, Glenner GG.	Related Articles, Links
	Amyloid. IV. Is human amyloid immunogenic? Int Arch Allergy Appl Immunol. 1968;34(3):269-82. No abstract a PMID: 4176084 [PubMed - indexed for MEDLINE]	vailable.
□ 212:	Burns J, Pennock CA, Stoward PJ.	Related Articles, Links
	The specificity of the staining of amyloid deposits with J Pathol Bacteriol. 1967 Oct;94(2):337-44. No abstract available. PMID: 4169244 [PubMed - indexed for MEDLINE]	thioflavine T.

☐ 213: Zschiesche W.

	Gegenbaurs Morphol .	ibition of experimenta Jahrb. 1967;111(2):313-7. Med - indexed for MEDLII	German. No al		
Display	Summary	• Show: 500 • Se	ort 🔻	Send to Text	¥
	Items 1-213 of 2	13		On	ne page.

Write to the Help Desk
NCBi | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Jan 29 2004 15:06:34

=> file BIOSCIENCE FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED FILE 'ADISCTI' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:10:44 ON 09 FEB 2004

FILE 'ANABSTR' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:10:44 ON 09 FEB 2004

FILE 'CAPLUS' ENTERED AT 15:10:44 ON 09 FEB 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:10:44 ON 09 FEB 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:10:44 ON 09 FEB 2004

FILE 'FOMAD' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:10:44 ON 09 FEB 2004

FILE 'HEALSAFE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:10:44 ON 09 FEB 2004

FILE 'NIOSHTIC' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:10:44 ON 09 FEB 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:10:44 ON 09 FEB 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:10:44 ON 09 FEB 2004 Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:10:44 ON 09 FEB 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:10:44 ON 09 FEB 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:10:44 ON 09 FEB 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:10:44 ON 09 FEB 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE PROCESSING IS APPROXIMATELY 23% COMPLETE FOR L1
PROCESSING IS APPROXIMATELY 52% COMPLETE FOR L1
PROCESSING IS APPROXIMATELY 85% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2 2319 DUP REM L1 (510 DUPLICATES REMOVED)

```
=> S L2 AND beta-amyloid
  22 FILES SEARCHED...
  44 FILES SEARCHED...
  60 FILES SEARCHED...
           726 L2 AND BETA-AMYLOID
=> S L3 AND PY<=1999
'1999' NOT A VALID FIELD CODE
   6 FILES SEARCHED...
   7 FILES SEARCHED...
  11 FILES SEARCHED...
  14 FILES SEARCHED...
  17 FILES SEARCHED...
1999' NOT A VALID FIELD CODE
  29 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
  40 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  46 FILES SEARCHED...
  49 FILES SEARCHED...
 1999' NOT A VALID FIELD CODE
  56 FILES SEARCHED...
  59 FILES SEARCHED...
            128 L3 AND PY<=1999
=> D L4 1-128
     ANSWER 1 OF 128 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ı 4
     1995:270290 BIOSIS
ΑN
     PREV199598284590
DN
     Hypothesis: Is Alzheimer's disease a metal-induced immune disorder?.
TI
     Armstrong, R. A. [Reprint author]; Winsper, S. J.; Blair, J. A.
ΑU
     Vision Sci., Aston Univ., Birmingham B4 7ET, UK
Neurodegeneration, (1995) Vol. 4, No. 1, pp. 107-111.
CS
S<sub>0</sub>
     ISSN: 1055-8330.
DT
     Article
     English
LA
     Entered STN: 26 Jun 1995
ED
     Last Updated on STN: 26 Jun 1995
L4
     ANSWER 2 OF 128 CANCERLIT on STN
     2000133621
                     CANCERLIT
ΑN
                 PubMed ID: 10668442
     20133621
DN
     Protective and rescuing abilities of IGF-I and some putative free radical
TI
                            ***beta*** - ***amyloid*** -inducing toxicity in
     scavengers against
     Dore S; Bastianetto S; Kar S; Quirion R
ΑIJ
     Douglas Hospital Research Center, McGill University, Montreal, Quebec,
CS
     Canada.
     ANNALS OF THE NEW YORK ACADEMY OF SCIENCES.
                                                       ***(1999)***
                                                                        890 356-64.
SO
     Journal code: 7506858. ISSN: 0077-8923.
     United States
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     MEDLINE; Priority Journals MEDLINE 2000133621
FS
os
EM
     200003
     Entered STN: 20000413
ED
     Last Updated on STN: 20000413
     ANSWER 3 OF 128 IFIPAT COPYRIGHT 2004 IFI on STN
L4
      03618637 IFIPAT; IFIUDB; IFICDB
AN
      OPTICAL DIAGNOSTIC AGENTS FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY
TI
      MEANS OF NEAR INFRARED RADIATION (NIR RADIATION); FOR THERAPY OF
      ALZHEIMER'S DISEASE
      Dyrks Thomas (DE); Licha Kai (DE); Riefke Bjorn (DE); Semmler Wolfhard
IN
       (DE); Turner Jonathan (DE)
       Schering AG DE (13811)
PA
PΙ
       US 6329531
                        B1 20011211
                            19980528
      wo 9822146
      US 1999-308177
                            19991118
ΑI
      WO 1997-DE2559
                            19971029
                                       PCT 371 date
                            19991118
```

PCT 102(e) date

19991118

```
20011211
      us 6329531
FI
      utility
DT
      CHEMICAL
FS
      GRANTED
      010411
                 MFN: 0073
MRN
      010463
                      0439
CLMN
      21
        2 Drawing Sheet(s), 2 Figure(s).
GΙ
L4
     ANSWER 4 OF 128
                           MEDLINE on STN
     1999334930
                      MEDLINE
ΑN
                  PubMed ID: 10408445
DN
     99334930
                            ***amyloid*** -beta attenuates Alzheimer-disease-like
     Immunization with
TI
     pathology in the PDAPP mouse.
     Comment in: Nature. 1999 Jul 8;400(6740):116-7
Comment in: Nature. 2002 Apr 18;416(6882):677
Schenk D; Barbour R; Dunn W; Gordon G; Grajeda H; Guido T; Hu K; Huang J; Johnson-Wood K; Khan K; Kholodenko D; Lee M; Liao Z; Lieberburg I; Motter
CM
ΑU
     R; Mutter L; Sóriano F; Shopp G; Vasquez N; Vandevert C; Walker S; Wogulis
     M; Yednock T; Games D; Seubert P
     Elan Pharmaceuticals, South San Francisco, California 94080, USA..
CS
     dschenk@elanpharma.com
                 ***(1999 Jul 8)*** 400 (6740) 173-7.
SO
     Journal code: 0410462. ISSN: 0028-0836.
     ENGLAND: United Kingdom
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
     Priority Journals
FS
     199907
EM
     Entered STN: 19990806
ED
     Last Updated on STN: 20020911
     Entered Medline: 19990723
     ANSWER 5 OF 128 PHIN COPYRIGHT 2004 PJB on STN
L4
     95:9713
AN
               PHIN
     s00444837
DN
     22 May 1995
DED
      Skandigen in 1994
ΤI
      Scrip ( ***1995***
                             )
                                No. 2036 p14
S0
     Newsletter
DT
FS
      FULL
     ANSWER 6 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
                       1999:802489 PROMT
ACCESSION NUMBER:
                       Schering-Plough Corp.
TITLE:
                       Humphreys, Andrew
AUTHOR(S):
                                        ***Sept 1997*** ) Vol. 16, No. 9, pp. 188.
SOURCE:
                       Med Ad News, (
                       ISSN: 0745-Ó9Ò7.
Engel Publishing Partners
PUBLISHER:
                       Newsletter
DOCUMENT TYPE:
                       English
LANGUAGE:
WORD COUNT:
                       6554
                       *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L4
     ANSWER 7 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
                       1999:525908 PROMT
ACCESSION NUMBER:
                       A Vaccine for Alzheimer's Disease?(Brief Article)
TITLE:
AUTHOR(S):
                       Travis, J.
                       Science News, ( ***10 Jul 1999*** ) Vol. 156, No. 2, pp.
SOURCE:
                       20.
                       ISSN: 0036-8423.
PUBLISHER:
                       Science Service, Inc.
                       Newsletter
DOCUMENT TYPE:
LANGUAGE:
                       English
                       773
WORD COUNT:
                       *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
    ANSWER 8 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
```

1999:439763

Leff. David N.

ACCESSION NUMBER:

TITLE:

AUTHOR(S):

PROMT

SHOT IN THE ARM FOR DEMENTIA TREATMENT?

```
American Health Consultants, Inc.
PUBLISHER:
DOCUMENT TYPE:
                     Newsletter
                     English
LANGUAGE:
                     1091
WORD COUNT:
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 9 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     1999:245576 PROMT
                     EUROPEAN PATENT DISCLOSURES.
TITLE:
                     BIOWORLD Today, ( ***13 Oct 1998*** ) Vol. 9, No. 197.
SOURCE:
                     American Health Consultants, Inc.
PUBLISHER:
                     Newsletter
DOCUMENT TYPE:
                     English
LANGUAGE:
WORD COUNT:
                     1605
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 10 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
14
ACCESSION NUMBER:
                     96:282171 PROMT
                     Signal Pharmaceuticals
TITLE:
                     Bioventure View, ( ***Jun 1996*** ) pp. N/A.
SOURCE:
                     ISSN: 0892-1903.
                     English
LANGUAGE:
WORD COUNT:
                       1531
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 11 OF 128 PROMT COPYRIGHT 2004 Gale Group on STN
                     94:505257 PROMT
ACCESSION NUMBER:
TITLE:
                     Clinical Update
                                         ***0ct 1994***
SOURCE:
                     Bioventure View, (
                                                            ) pp. N/A.
                     ISSN: 0892-1903.
                    English
LANGUAGE:
WORD COUNT:
                        2612
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L4
     ANSWER 12 OF 128 USPATFULL on STN
ΑN
       2003:337293 USPATFULL
       Use of phanquinone for the treatment of alzheimer's disease
TI
       Xilinas, Michel, Memeou, FRANCE
IN
       Gerolymatos, Panayotis Nikolas, Kryoneri Attika, GREECE
P.N. Gerolymatos S.A., Kyroneri Attika, GREECE (non-U.S. corporation)
PA
       us 6670369
                            в1
                                 20031230
PΙ
                    19990304
       wo 9909981
                                                                         <--
       us 2000-485909
                                 20001019 (9)
AI
       wo 1998-IB1095
                                 19980717
                                 20001019
                                           PCT 371 date
       GR 1997-970100330
                             19970821
PRAI
       GR 1997-970100507
                             19971231
       Utility
DT
       GRANTED
FS
LN.CNT 802
       INCLM: 514/282.000
INCL
       INCLS: 514/296.000; 514/298.000; 514/003.100
NCL
       NCLM:
               514/282.000
       NCLS:
               514/296.000; 514/298.000
IC
        [7]
       ICM: A61K031-44
       ICS: A61K031-47
       514/311; 514/292; 514/296; 514/298
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 13 OF 128 USPATFULL on STN
       2003:285263 USPATFULL
AN
       Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
TI
IN
       Li, Hui, Vernon Hills, IL, United States
       Becker, Daniel P., Glenview, IL, United States
       Villamil, Clara I., Glenview, IL, United States
Boehm, Terri L., Ballwin, MO, United States
       Getman, Daniel P., Chesterfield, MO, United States
       McDonald, Joseph J., Ballwin, MO, United States
       DeCrescenzo, Gary A., St. Charles, MO, United States
       Pharmacia Corporation, Skokie, IL, United States (U.S. corporation)
PΔ
```

PΙ

US 6638952

в1

20031028

```
19991223 (9)
        us 1999-254530
ΑI
        wo 1998-US4273
                                    19980304
                               19970304 (60)
        US 1997-35182P
PRAI
        Utility
DT
        GRANTED
FS
LN.CNT 2682
        INCLM: 514/330.000
INCL
        INCLS: 546/221.000
                514/330.000
NCL
        NCLM:
                546/221.000
        NCLS:
        [7]
IC
        ICM: A61K031-445
        ICS: C07D211-22
        514/330; 546/221
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 14 OF 128 USPATFULL ON STN
        2003:89394 USPATFULL
AN
        Aromatic sulfone hydroxamic acid metalloprotease inhibitor
TI
IN
        Barta, Thomas E., Evanston, IL, United States
        Becker, Daniel P., Glenview, IL, United States
        Boehm, Terri L., Ballwin, MO, United States
        De Crescenzo, Gary A., St. Charles, MO, United States
        Villamil, Clara I., Glenview, IL, United States
McDonald, Joseph J., Ballwin, MO, United States
Freskos, John N., Clayton, MO, United States
Getman, Daniel P., Chesterfield, MO, United States
        G. D. Searle & Company, St.Louis, MO, United States (U.S. corporation)
PA
                                     20030401
        US 6541489
PΙ
                               В1
                      19990527
                                                                                 <---
        wo 9925687
                                     20000731 (9)
        us 2000-554082
ΑI
        wo 1998-US23242
                                     19981112
                                     20000731
                                                PCT 371 date
                                19971114 (60)
PRAI
        US 1997-66007P
        Utility
DT
        GRANTED
FS
LN.CNT 13579
        INCLM: 514/330.000
INCL
        INCLS: 546/192.000; 546/225.000
                514/330.000
NCL
        NCLM:
        NCLS:
                546/192.000; 546/225.000
        [7]
IC
        ICM: A61K031-445
        ICS: C07D211-06
EXF
        546/192; 546/225; 514/330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 15 OF 128 USPATFULL ON STN
L4
        2002:290938 USPATFULL
AN
        N-hydroxy 4-sulfonyl butanamide compounds
TI
        Villamil, Clara I., Glenview, IL, United States
Freskos, John N., Clayton, MO, United States
IN
        Mischke, Brent V., Defiance, MO, United States
        Mullins, Patrick B., St. Louis, MO, United States
        Heintz, Robert M., Ballwin, MO, United States
        Getman, Daniel P., Chesterfield, MO, United States
        McDonald, Joseph J., Ballwin, MO, United States
        DeCrescenzo, Gary A., St. Charles, MO, United States
        Barta, Thomas E., Evanston, IL, United States
        Becker, Daniel P., Glenview, IL, United States
        Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PA
PI
        us 6476027
                               в1
                                     20021105
                     19980911
        wo 9839316
                                                                                 <--
        US 1999-254531
                                     19991206 (9)
ΑI
        wo 1998-US4297
                                     19980304
                                     19991206 PCT 371 date
PRAI
        US 1997-35182P
                                19970304 (60)
        Utility
DT
        GRANTED
FS
LN.CNT 3634
        INCLM: 514/237.800
INCL
        INCLS: 514/330.000; 514/331.000; 514/357.000; 514/428.000; 514/486.000; 514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000; 546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000
```

NCL

NCLM:

514/237.800

```
514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000;
                     546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000
          [7]
IC
          ICM: A61K031-16
          ICS: A61K031-4406; C07C323-32; C07D211-90
562/621; 562/623; 546/225; 546/226; 546/233; 546/340; 544/159; 548/568;
560/13; 514/237.8; 514/330; 514/331; 514/357; 514/428; 514/456; 514/575
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
       ANSWER 16 OF 128 USPATFULL on STN
          2002:239013 USPATFULL
AN
          Amidoaromatic ring sulfonamide hydroxamic acid compounds
TI
          Heintz, Robert M., Ballwin, MO, United States
Getman, Daniel P., Chesterfield, MO, United States
McDonald, Joseph J., Ballwin, MO, United States
IN
          DeCrescenzo, Gary A., St. Charles, MO, United States
          Howard, Susan C., Fenton, MO, United States
          Abbas, S. Zaheer, St. Louis, MO, United States
PA
          Monsanto Company, Skokie, IL, United States (U.S. corporation)
                                              20020917
          us 6451791
PI
                                      В1
          wo 9839329
                           19980911
                                                                                                     <--
          US 1999-230205
                                              19990604 (9)
ΑI
          wo 1998-US4299
                                              19980304
                                              19990604 PCT 371 date
                                       19970304 (60)
PRAI
          US 1997-39795P
          Utility
DT
          GRANTED
FS
LN.CNT 3139
          INCLM: 514/238.200
INCL
          INCLS: 514/231.500; 514/231.800; 514/235.500; 514/316.000; 514/318.000; 514/342.000; 514/343.000; 514/357.000; 514/365.000; 514/438.000; 514/471.000; 514/539.000; 514/603.000; 544/085.000; 544/124.000;
                                        544/131.000; 544/133.000; 544/137.000;
                                                                                                  544/141.000;
                     544/130.000;
                     544/146.000;
                                       544/148.000; 544/160.000; 546/194.000; 546/233.000;
                     546/234.000; 546/236.000; 546/237.000; 546/247.000; 546/265.000; 546/337.000; 546/338.000; 548/204.000; 549/065.000; 549/426.000;
                     560/013.000; 564/086.000
                     514/238.200
NCL
          NCLM:
                    514/231.500; 514/231.800; 514/235.500; 514/316.000; 514/318.000; 514/342.000; 514/343.000; 514/357.000; 514/365.000; 514/438.000; 514/471.000; 514/539.000; 514/603.000; 544/085.000; 544/124.000;
          NCLS:
                     544/130.000; 544/131.000; 544/133.000; 544/137.000; 544/141.000;
                     544/146.000; 544/148.000; 544/160.000; 546/194.000; 546/233.000;
                    546/234.000; 546/236.000; 546/237.000; 546/247.000; 546/265.000; 546/337.000; 546/338.000; 548/204.000; 549/065.000; 549/426.000;
                     560/013.000; 564/086.000
IC
           [7]
           ICM: A61K031-18
          ICS: A61K031-24; A61K031-34; A61K031-535
514/238.2; 514/357; 514/539; 514/603; 514/231.5; 514/231.8; 514/237.2;
514/235.5; 514/316; 514/318; 514/342; 514/343; 514/365; 514/438;
EXF
          514/471; 544/160; 544/85; 544/124; 544/130; 544/133; 544/131; 544/146; 544/137; 544/141; 544/148; 546/338; 546/194; 546/247; 546/233; 546/234; 546/236; 546/237; 546/265; 546/337; 560/13; 564/86; 548/204; 549/65;
          549/426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
       ANSWER 17 OF 128 USPATFULL ON STN
          2002:224607 USPATFULL
AN
          Stable hyperforin salts, method for producing same and their use in the
TI
          treatment of alzheimer's disease
          Chatterjee, Shyam Sunder, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
IN
          Erdelmeier, Clemens, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
          Klessing, Klaus, Ettlingen, GERMANY, FEDERAL REPUBLIC OF
Marme, Dieter, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Schachtele, Christoph, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Willmar Schwabe GmbH & Co., Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
PA
          (non-U.S. corporation)
          US 6444662
                                              20020903
PΙ
          wo 9941220 19990819
                                                                                                     <--
                                              20000811 (9)
ΑI
          US 2000-622151
          WO 1999-EP737
                                              19990204
                                              20000811 PCT 371 date
          DE 1998-19805947
PRAI
                                        19980213
DT
          Utility
```

```
LN.CNT 929
INCL
          INCLM: 514/210.010
          INCLS: 514/212.010; 514/218.000; 514/227.500; 514/231.200; 514/252.100; 514/252.110; 514/256.000; 514/277.000; 514/315.000; 514/365.000; 514/374.000; 514/406.000; 514/408.000; 514/691.000; 540/575.000; 540/579.000; 540/612.000; 544/059.000; 544/107.000;
                                        544/358.000; 544/410.000;
                     544/242.000;
                                                                              548/146.000;
                                                                                                  548/235.000;
                     548/335.100; 548/373.100; 548/565.000; 548/579.000; 548/950.000;
                     548/366.000; 548/374.000; 536/366.000; 536/374.000
                     514/210.010
NCL
          NCLM:
                    514/212.010; 514/218.000; 514/227.500; 514/231.200; 514/252.100; 514/252.110; 514/256.000; 514/277.000; 514/315.000; 514/365.000; 514/374.000; 514/406.000; 514/408.000; 514/691.000; 540/544.000; 540/575.000; 540/579.000; 540/612.000; 544/059.000; 544/107.000; 548/235.000; 548/335.100; 548/356.100; 548/373.100; 548/565.000; 548/579.000;
          NCLS:
                     548/950.000
IC
           [7]
          ICM: C07C050-36
          ICS: A61K035-78
          514/210.01; 514/211.01; 514/212.01; 514/218; 514/227.5; 514/231.2; 514/252.1; 514/252.11; 514/256; 514/277; 514/315; 514/365; 514/374; 514/396; 514/406; 514/408; 514/691; 540/544; 540/575; 540/412; 544/59; 544/107; 544/242; 544/358; 548/410; 548/146; 548/235; 548/335.1;
EXF
           548/373.1; 548/565; 548/579; 548/950; 568/366; 568/374; 568/389;
          568/457; 568/459; 568/503; 568/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 18 OF 128 USPATFULL on STN
L4
          2002:115819 USPATFULL
ΑN
          Fibrinogen-coated particles for therapeutic use
TT
          Yen, Richard C. K., Yorba Linda, CA, United States
IN
          Hemosphere, Inc., Anaheim, CA, United States (U.S. corporation)
PA
                                              20020521
PΙ
          US 6391343
                                       В1
                            19961212
          wo 9639128
          us 1998-952765
                                               19980410 (8)
AΙ
                                              19960604
          wo 1996-US9458
                                              19980410
                                                            PCT 371 date
          Continuation-in-part of Ser. No. US 1995-554919, filed on 9 Nov 1995, now abandoned Continuation-in-part of Ser. No. US 1995-471650, filed on 6 Jun 1995, now patented, Pat. No. US 5725804 Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US
RLI
           5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun
           1993, now abandoned Continuation-in-part of Ser. No. US 1992-959560,
          filed on 13 Oct 1992, now patented, Pat. No. US 5308620
          Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991,
          now abandoned
DT
          Utility
FS
           GRANTED
LN.CNT 2407
          INCLM: 424/491.000
INCL
           INCLS: 424/078.060; 427/002.140; 514/002.000; 514/834.000; 514/937.000;
                     514/951.000; 516/077.000
                     424/491.000
NCL
          NCLM:
                     424/078.060; 427/002.140; 514/002.000; 514/834.000; 514/937.000; 514/951.000; 516/077.000
          NCLS:
           [7]
IC
           ICM: A61K009-16
           ICS: A61K038-36; A61K038-38
           264/4.3; 427/2.14; 427/2.21; 427/213.3; 427/213.33; 424/78.06; 424/491; 424/493; 514/2; 514/834; 514/937; 514/951; 514/965; 516/77
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 19 OF 128 USPATFULL ON STN
L4
           2002:88521 USPATFULL
AN
TI
           Furan nitrone compounds
           Kelleher, Judith A., Fremont, CA, United States
IN
          Maples, Kirk R., San Jose, CA, United States
Waterbury, Lowell David, San Carlos, CA, United States
          Wilcox, Allan L., Mountain View, CA, United States
          Xu, Hong, Cupertino, CA, United States
          Zhang, Yong-Kang, Santa Clara, CA, United States
           Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.
PA
           corporation)
```

20020423

R1

PΙ

US 6376540

```
us 1999-230065
                                          19991217 (9)
ΑI
                                          19970714
         wo 1997-us11960
                                          19991217
                                                       PCT 371 date
         US 1996-22169P
                                     19960719 (60)
PRAI
         Utility
DT
         GRANTED
FS
LN.CNT
         2012
         INCLM: 514/471.000
INCL
         INCLS: 514/231.500; 514/254.100
                   514/471.000
NCL
         NCLM:
                  514/231.500; 514/254.100
         NCLS:
IC
          [7]
         ICM: A61K031-34
ICS: A61K031-535; A61K031-497

EXF 514/471; 514/254.1; 514/231.5; 549/475; 549/491; 544/152; 544/359

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 20 OF 128 USPATFULL on STN
L4
ΑN
         2002:63903 USPATFULL
         Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
TI
         Freskos, John N., Clayton, MO, United States
Boehm, Terri L., Ballwin, MO, United States
Mischke, Brent V., Defiance, MO, United States
Heintz, Robert M., Ballwin, MO, United States
McDonald, Joseph J., Ballwin, MO, United States
IN
         DeCrescenzo, Gary A., St. Charles, MO, United States
         Howard, Susan C., Fenton, MO, United States
         G. D. Searle & Company, Skokie, IL, United States (U.S. corporation)
PA
                                          20020326
                                   В1
PΙ
         US 6362183
         wo 9839326 19980911
                                                                                             <--
         us 1999-254535
                                          19990604 (9)
ΑI
         wo 1998-US4277
                                          19980304
                                          19990604 PCT 371 date
                                     19970304 (60)
         US 1997-35182P
PRAI
         Utility
DT
          GRANTED
FS
LN.CNT 3648
          INCLM: 514/238.200
INCL
         INCLS: 514/355.000; 514/575.000; 544/159.000; 544/318.000; 544/336.000; 544/122.000; 544/130.000; 544/131.000; 544/120.000; 544/137.000; 544/059.000; 544/135.000; 544/139.000; 544/140.000; 544/128.000;
                   544/152.000; 544/146.000;
                                                       546/152.000; 546/139.000; 546/247.000;
                                                                        562/621.000; 564/049.000;
                   546/316.000; 546/336.000; 546/280.100;
                   564/300.000; 564/158.000; 564/162.000;
                                                                        564/188.000; 564/189.000;
                   564/190.000; 564/191.000; 564/123.000; 548/221.000
548/233.000; 548/234.000; 548/236.000; 548/235.000
548/324.100; 548/324.500; 548/567.000; 548/568.000
                                                                        548/221.000; 548/222.000;
548/235.000; 548/304.400;
                   514/238.200
514/355.000; 514/575.000; 544/059.000; 544/120.000; 544/122.000;
          NCLM:
NCL
          NCLS:
                   544/128.000; 544/130.000; 544/131.000;
                                                                        544/135.000; 544/137.000;
                   544/139.000; 544/140.000; 544/146.000;
                                                                        544/152.000; 544/159.000;
                                                                        546/152.000; 546/247.000;
                   544/318.000; 544/336.000; 546/139.000;
                   546/280.100; 546/316.000; 546/336.000;
                                                                        548/221.000; 548/222.000;
                                                                        548/236.000; 548/304.400;
548/568.000; 562/621.000;
564/162.000; 564/188.000;
                   548/233.000; 548/234.000; 548/235.000; 548/236.000; 548/324.100; 548/324.500; 548/567.000; 548/568.000; 564/049.000; 564/123.000; 564/158.000; 564/162.000; 564/189.000; 564/190.000; 564/191.000; 564/300.000
          [7]
IC
          ICM: C07D403-02
          ICS: c07D403-12; c07D413-02; c07D279-12; c07D333-06
          514/238.2; 514/355; 514/575; 544/159; 546/316; 562/621
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
       ANSWER 21 OF 128 USPATFULL on STN
ΑN
          2001:173346 USPATFULL
          Diagnostic method for Alzheimer's disease
TI
          Alkon, Daniel L., Bethesda, MD, United States
IN
          The United States of America as represented by the Department of Health
PA
          and Human Services, Washington, DC, United States (U.S. corporation)
                                          20011009
ΡI
          US 6300085
                                    в1
                         19960404
          wo 9610182
                                                                                             <--
          US 1997-809646
WO 1995-US12433
                                          19970718 (8)
ΑI
                                          19950926
                                          19970718
                                                       PCT 371 date
                                          19970718 PCT 102(e) date
```

```
now patented, Pat. No. US 5976816 Continuation-in-part of Ser. No. US
       1993-56456, filed on 3 May 1993, now patented, Pat. No. US 5580748
       Utility
DT
       GRANTED
FS
       2376
LN.CNT
       INCLM: 435/007.210
INCL
       INCLS: 436/063.000; 436/172.000; 436/811.000
               435/007.210
NCL
               436/063.000; 436/172.000; 436/811.000
       NCLS:
       T71
IC
       ICM: G01N033-53
       ICS: G01N033-48
435/7.1; 435/7.21; 435/7.24; 435/7.92; 435/7.94; 435/7.95; 436/518; 436/528; 436/530; 436/531; 436/63; 436/811; 436/172
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 22 OF 128 USPATFULL on STN
14
       2001:26018 USPATFULL
AN
       Protein and monoclonal antibody specific thereto
TI
       Seiki, Motoharu, Shinagawa, Japan
ΙN
       Sato, Hiroshi, Kanazawa, Japan
       Shinagawa, Akira, Takaoka, Japan
       Fuji Yakuhin Kogyo Kabushiki Kaisha, Toyama, Japan (non-U.S.
PA
       corporation)
       US 6191255
                                 20010220
PI
                            в1
       wo 9704080
                    19970206
       us 1998-41
                                 19980220 (9)
ΑI
       WO 1996-JP1956
                                 19960712
                                            PCT 371 date
                                 19980220
                                 19980220
                                           PCT 102(e) date
                             19950714
PRAI
       JP 1995-200319
       JP 1995-200320
                             19950714
       Utility
DT
       Granted
FS
LN.CNT 2653
INCL
       INCLM: 530/324.000
       INCLS: 530/400.000; 536/023.200; 536/023.500; 536/024.310; 435/069.100;
               435/320.100; 435/325.000
       NCLM:
               530/324.000
NCL
               435/069.100; 435/320.100; 435/325.000; 530/400.000; 536/023.200;
       NCLS:
               536/023.500; 536/024.310
       [7]
IC
       ICM: A61K038-43
       ICS: C07K001-00; C07H021-04
       530/324; 530/400; 536/23.5; 536/23.2; 536/24.31; 435/69.1; 435/320.1;
EXF
       435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 23 OF 128 USPATFULL on STN
       2000:91930 USPATFULL
AN
TI
       Treatment of neurological conditions by an interleukin-1 inhibiting
       compound
       Rothwell, Nancy Jane, Poulton-le-Fylde, United Kingdom
ΙN
       Roberts, Gareth, London, United Kingdom
       The Victoria University of Manchester, Manchester, United Kingdom
PA
        (non-U.S. corporation)
       us 6090775
PΙ
                                 20000718
       wo 9308820
                    19930513
                                                                         <--
       us 1994-232167
                                 19940729 (8)
ΑI
       WO 1992-GB2023
                                 19921102
                                 19940729
                                            PCT 371 date
                                 19940729
                                           PCT 102(e) date
PRAI
       GB 1991-23161
                             19911031
       GB 1991-25670
                             19911130
DT
       Utility
FS
       Granted
LN.CNT 476
       INCLM: 514/002.000
INCL
       INCLS: 514/012.000; 424/085.200; 530/350.000; 530/351.000
               514/002.000
NCL
       NCLM:
               424/085.200; 514/012.000; 530/350.000; 530/351.000
       NCLS:
IC
       [7]
       ICM: A61K038-00
       ICS: A61K038-20
EXF
       514/2; 514/12; 530/350; 530/351; 424/85.2
```

```
ANSWER 24 OF 128 USPATFULL ON STN
L4
        2000:88188 USPATFULL
ΑN
        Thioaryl sulfonamide hydroxamic acid compounds
TI
        Getman, Daniel P., 66 Sunny Hill Ct., Chesterfield, MO, United States
IN
        Becker, Daniel P., 1800 Mapelwood La., Glenview, IL, United States
        60025
        Barta, Thomas E., 1133 Maple Ave. #3W, Evanston, IL. United States
        60202
        Villamil, Clara I., 813 Long Rd., Glenview, IL, United States 60025
        Hockerman, Susan L., 5319 W. Hutchingson, Chicago, IL, United States
        60641
        Bedell, Louis J., 1832 E. Campl McDonald Rd., Mt. Prospect, IL, United
        States
        Li, Hui, 322 Jefferson Ct., Vernon Hills, IL, United States 60061 Freskos, John N., 7572 York, Clayton, MO, United States 63105 Heintz, Robert M., 603 Nancy Pl., Ballwin, MO, United States 63021
        McDonald, Joseph J., 1036 Johanna Dr., Ballwin, MO, United States 63021
DeCrescenzo, Gary A., 7345 Spruce Hill Ct., St. Charles, MO, United
        States 63304
PΙ
        us 6087359
                                      20000711
                       19980911
        wo 9839313
        us 1999-254534
                                      19990910 (9)
ΑI
        wo 1998-US4298
                                      19980304
                                      19990910
                                                  PCT 371 date
                                      19990910
                                                  PCT 102(e) date
PRAI
        US 1997-39795P
                                 19970304 (60)
        Utility
DT
        Granted
FS
LN.CNT 2441
        INCLM: 514/238.200
INCL
                 544/116.000; 544/120.000; 544/122.000; 544/127.000; 544/128.000;
        INCLS:
                 544/131.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000;
                 544/138.000; 544/139.000; 544/141.000; 544/143.000; 544/144.000;
                 544/145.000; 544/146.000; 544/148.000; 544/149.000; 544/153.000;
                 544/159.000; 546/234.000
                 514/238.200
NCL
        NCLM:
                 544/116.000; 544/120.000; 544/122.000; 544/127.000; 544/128.000; 544/131.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000; 544/138.000; 544/141.000; 544/143.000; 544/144.000; 544/145.000; 544/148.000; 544/149.000; 544/153.000;
        NCLS:
                 544/159.000; 546/234.000
IC
        [7]
        ICM: A61K031-5375
        ICS: A61K031-5377; C07D295-15; C07D413-12 544/159; 544/141; 514/238.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 25 OF 128 USPATFULL ON STN
        2000:34418 USPATFULL
AN
TI
        Defective DNA viral vector comprising a neural tissue-specific promoter
        for in vivo expression of a gene
        Kaplitt, Michael G., New York, NY, United States
IN
        The Rockefeller University, New York, NY, United States (U.S.
PA
        corporation)
                                      20000321
        US 6040172
PΙ
        wo 9404695
                       19940303
                                                                                   <--
        US 1995-381924
                                      19950214 (8)
ΑI
        wo 1993-US7685
                                      19930816
                                      19950214
                                                  PCT 371 date
                                      19950214 PCT 102(e) date
        Continuation-in-part of Ser. No. US 1992-930875, filed on 14 Aug 1992,
RLI
        now_abandoned
DT
        Utility
        Granted
FS
LN.CNT 787
        INCLM: 435/320.100
INCL
        INCLS: 435/455.000; 435/456.000; 435/457.000; 435/069.100; 435/069.800;
                 435/325.000; 424/093.210; 514/044.000; 800/009.000
                 435/320.100
        NCLM:
NCL
                 424/093.210; 435/069.100; 435/069.800; 435/325.000; 435/455.000; 435/456.000; 435/457.000; 514/044.000; 800/009.000
        NCLS:
        [7]
IC
```

ICM: C12N015-63

```
514/44; 800/2; 800/9; 435/320.1; 435/172.3; 435/69.1; 435/69.8; 435/325;
EXF
        435/455; 435/456; 435/457; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 26 OF 128 USPATFULL ON STN
L4
        1999:170613 USPATFULL
ΑN
        Method for treating Alzheimer's disease with folic acid
TI
        Smith, Anthony David, Oxford, United Kingdom
ΙN
        Jobst, Kim Anthony, Glasgow, United Kingdom
        Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.
PA
        corporation)
                                      19991228
                                                                                   <--
        us 6008221
PI
        us 1997-959035
                                      19971028 (8)
ΑI
DT
        Utility
        Granted
FS
LN.CNT 1270
        INCLM: 514/254.000
INCL
        INCLS: 514/258.000
NCL
        NCLM: 514/250.000
IC
         [6]
        ICM: A61K031-495
        ICS: A61K031-50; A61K031-505
        514/254; 514/258
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 27 OF 128 USPATFULL ON STN
        1999:170258 USPATFULL
ΑN
        Reversing the formation of advanced glycosylation endproducts
TI
        Cerami, Anthony, Shelter Island, NY, United States
IN
        Ulrich, Peter C., Old Tappan, NJ, United States Wagle, Dilip R., Valley Cottage, NY, United States Hwang, San-Bao, Sudbury, MA, United States Vasan, Sara, Yonkers, NY, United States
        Egan, John J., Mountain Lakes, NJ, United States
        Alteon Inc., United States (U.S. corporation)
PA
        The Picower Institute for Medical Research, United States (U.S.
         corporation)
        us 6007865
                                      19991228
PΙ
        US 1997-971878
                                      19971119 (8)
AT
        Division of Ser. No. US 1996-588249, filed on 18 Jan 1996, now patented,
RLI
        Pat. No. US 5853703 which is a continuation of Ser. No. US 1995-473184,
        filed on 7 Jun 1995, now abandoned which is a continuation of Ser. No.
        US 1995-375155, filed on 18 Jan 1995, now patented, Pat. No. US 5656261
DT
        Utility
        Granted
FS
LN.CNT 2190
INCL
        INCLM: 426/656.000
                 514/365.000; 514/367.000; 514/398.000; 514/399.000; 514/400.000;
                 514/561.000;
                                 514/562.000; 548/152.000; 548/161.000; 548/164.000;
                 548/179.000; 548/180.000; 548/190.000; 548/193.000; 548/194.000;
                 548/202.000; 548/203.000; 548/204.000; 548/205.000; 548/326.500;
                 548/331.100; 548/331.500; 562/555.000; 562/557.000
                 426/656.000
NCL
        NCLM:
                 514/365.000; 514/367.000; 514/398.000; 514/399.000; 514/400.000; 514/561.000; 514/562.000; 548/152.000; 548/161.000; 548/164.000; 548/179.000; 548/180.000; 548/190.000; 548/193.000; 548/194.000; 548/202.000; 548/203.000; 548/204.000; 548/205.000; 548/326.500;
        NCLS:
                 548/331.100; 548/331.500; 562/555.000; 562/557.000
         [6]
IC
         ICM: A61K031-38
         ICS: C07D277-24
        514/365; 514/367; 514/398; 514/399; 514/400; 514/561; 514/562; 548/152; 548/161; 548/164; 548/179; 548/180; 548/190; 548/193; 548/194; 548/202; 548/203; 548/204; 548/205; 548/326.5; 548/331.1; 548/331.5; 562/555;
EXF
        548/203; 548/204
562/557; 426/656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 28 OF 128 USPATFULL on STN
        1999:166976 USPATFULL
ΑN
                                       ***amyloid***
TT
        Method of use of serum
                                                          a protein
        Kisilevsky, Robert, Kingston, Canada
IN
        Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)
PA
                                      19991221
        us 6004936
ΡI
        US 1995-458054
                                      19950601 (8)
ΑI
        Continuation-in-part of Ser. No. US 1994-203010, filed on 28 Feb 1994,
RLI
```

```
1992-890936, filed on 29 May 1992, now patented, Pat. No. US 5318958,
       issued on 7 Jun 1994
       Utility
DT
       Granted
FS
LN.CNT 1276
       INCLM: 514/021.000
INCL
       INCLS: 514/002.000; 514/012.000
               514/021.000
NCL
       NCLM:
       NCLS:
               514/002.000; 514/012.000
       [6]
IC
       ICM: A61K038-17
       514/21; 514/2; 514/12
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 29 OF 128 USPATFULL on STN
L4
       1999:163707 USPATFULL
AN
       Clioquinol for the treatment of Alzheimer's disease
TI
       Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
ΙN
       P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)
PA
                                 19991214
PΙ
       us 6001852
                                 19980213 (9)
       us 1998-23544
ΑI
       Continuation-in-part of Ser. No. WO 1997-IB983, filed on 8 Aug 1997
RLI
       GR 1996-960100286
                             19960813
PRAI
DT
       Utility
       Granted
FS
LN.CNT 1170
       INCLM: 514/311.000
INCL
       INCLS: 514/052.000
NCL
               514/311.000
               514/052.000
       NCLS:
TC
       [6]
       ICM: A61K031-70
        ICS: A61K031-47
       514/311; 514/52
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 30 OF 128 USPATFULL ON STN
       1999:163188 USPATFULL
ΑN
                            ***amvloid***
       Method of imaging
                                              deposits
TI
       Caprathe, Bradley W., Livonia, MI, United States
IN
       Gilmore, John L., Ann Arbor, MI, United States
       Hays, Sheryl J.,_Ann Arbor, MI, United States
       Jaen, Juan C., Plymouth, MI, United States
       LeVine, III, Harry, Ann Arbor, MI, United States
       Warner-Lambert Company, Morris Plains, NJ, United States (U.S.
PA
       corporation)
       US 6001331
                                  19991214
                                                                          <--
PΙ
                    19970731
       wo 9726919
       US 1998-117101
                                  19980722 (9)
ΑI
       wo 1997-US251
                                  19970102
                                  19980722
                                            PCT 371 date
                                  19980722
                                            PCT 102(e) date
PRAI
       US 1996-10495P
                             19960124 (60)
       Utility
DT
FS
       Granted
LN.CNT 1652
        INCLM: 424/009.100
INCL
        INCLS: 424/001.110; 424/001.650; 424/001.810; 424/001.850; 548/400.000;
               536/102.000; 536/123.100
NCL
       NCLM:
               424/009.100
               424/001.110; 424/001.650; 424/001.810; 424/001.850; 536/102.000;
       NCLS:
               536/123.100; 548/400.000
IC
        [6]
        ICM: A61K049-00
        ICS: G01N031-00; G01N033-48
       424/1.11; 424/1.65; 424/1.81; 424/1.85; 424/1.73; 424/9.1; 548/400; 536/123.1; 536/18.7; 536/107; 536/102; 106/206.1; 106/216.1; 106/145.1;
EXF
        106/207.5; 514/23; 127/28; 127/22; 127/59; 127/25; 527/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 31 OF 128 USPATFULL ON STN
AN
       1999:155781 USPATFULL
       Arylsulfonamides as phospholipase A.sub.2 inhibitors
TI
       John, Varghese, San Francisco, CA, United States
Rydel, Russell E., Belmont, CA, United States
IN
```

```
Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       us 5994398
                                  19991130
                                                                           <--
PT
       us 1996-766554
                                  19961211 (8)
ΑI
       Utility
DT
       Granted
FS
       1939
LN.CNT
       INCLM: 514/485.000
INCL
       INCLS: 514/597.000; 514/603.000; 558/241.000; 560/012.000; 564/049.000;
               564/086.000
               514/485.000
NCL
       NCLM:
               514/597.000; 514/603.000; 558/241.000; 560/012.000; 564/049.000;
       NCLS:
               564/086.000
IC
        [6]
        ICM: A01N047-10
        ICS: A01N047-28; C07C333-00; C07C273-00
       560/12; 558/241; 564/49; 564/86
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 32 OF 128 USPATFULL on STN
L4
       1999:155706 USPATFULL
ΑN
       Pharmaceutical compositions comprising clioquinol in combination with
TI
       vitamin B12 and therapeutic and prophylactic uses thereof
       Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
ΙN
       P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)
PA
       us 5994323
                                  19991130
PΙ
       us 1998-23542
                                  19980213 (9)
ΑI
       GR 1997-970100507
                              19971231
PRAI
DT
       Utilitý
       Granted
FS
LN.CNT 1039
        INCLM: 514/052.000
INCL
               514/305.000; 514/306.000; 514/308.000
        INCLS:
               514/052.000
NCL
       NCLM:
       NCLS:
               514/305.000; 514/306.000; 514/308.000
IC
        [6]
        ICM: A61K031-70
        ICS: A61K031-44; A61K031-47
514/52; 514/305; 514/306; 514/308
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 33 OF 128 USPATFULL on STN
        1999:155676 USPATFULL
ΑN
TI
        Peptidyl compounds and their therapeutic use
        Baxter, Andrew Douglas, Cambridge, United Kingdom
IN
       Montana, John, Cambridge, United Kingdom
       Owen, David Alan, Cambridge, United Kingdom
Darwin Discovery Ltd., United Kingdom (non-U.S. corporation)
PA
       us 5994293
                                  19991130
PI
       US 1996-644381
AΤ
                                  19960510 (8)
       GB 1995-9404
                              19950510
PRAI
        GB 1995-25646
                              19951215
                              19960404
        GB 1996-7154
DT
       Utility
FS
        Granted
       1451
LN.CNT
        INCLM: 514/002.000
INCL
        INCLS: 514/019.000; 530/331.000; 530/868.000; 424/184.100; 424/185.100;
                260/998.200
NCL
       NCLM:
                514/002.000
               260/998.200; 424/184.100; 424/185.100; 514/019.000; 530/331.000;
        NCLS:
                530/868.000
IC
        [6]
        ICM: C07K005-00
        ICS: A61K038-05
        514/2; 514/19; 530/868; 530/331; 260/998.2; 424/184.1; 424/185.1
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 34 OF 128 USPATFULL on STN
        1999:151190 USPATFULL
ΑN
       Human ena/VASP-like protein splice variant
Lal, Preeti, Santa Clara, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
TI
IN
        Corley, Neil C., Mountain View, CA, United States
PA
        Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
```

```
us 5990087
                                  19991123
                                                                           <--
PΙ
                                  19990108 (9)
       us 1999-227420
ΑI
       Division of Ser. No. US 1998-26587, filed on 20 Feb 1998
RLI
       Utility
DT
       Granted
FS
LN.CNT 2477
        INCLM: 514/012.000
INCL
       INCLS: 514/021.000; 530/350.000; 530/849.000
       NCLM:
               514/012.000
NCL
               514/021.000; 530/350.000; 530/849.000
       NCLS:
IC
        Γ61
        ICM: A61K038-17
        ICS: C07K014-435
        514/12; 514/21; 530/350; 530/849
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 35 OF 128 USPATFULL on STN
L4
        1999:146753 USPATFULL
ΑN
        Genetic sequences and proteins related to alzheimer's disease
TI
TN
        St. George-Hyslop, Peter H., Toronto, Canada
        Rommens, Johanna M., Toronto, Canada
        Fraser, Paul E., Toronto, Canada
        The Hospital for Sick Children, HSC Research and Development Limited
PA
        Partnership, Canada (non-U.S. corporation)
The Governing Council of the University of Toronto, Canada (non-U.S.
        corporation)
        us 5986054
                                  19991116
PΙ
                                  19960126 (8)
        us 1996-592541
ΑI
        Continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
RLI
        which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
        filed on 28 Apr 1995
DT
        Utility
FS
        Granted
LN.CNT 7292
        INCLM: 530/350.000
INCL
        INCLS: 435/069.100
        NCLM: 530/350.000
NCL
        NCLS: 435/069.100
        [6]
TC
        ICM: C07K014-00
        ICS: C12P021-06
        530/350; 435/69.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 36 OF 128 USPATFULL ON STN
L4
        1999:146635 USPATFULL
ΑN
        Method of preventing and delaying onset of Alzheimer's disease and
TI
        composition therefor
        Novak, Egon, Richmond, Canada
IN
        Forbes Medi-Tech, Inc., Vancouver, Canada (non-U.S. corporation)
PA
        us 5985936
                                   19991116
PΙ
ΑI
        us 1997-993901
                                   19971218 (8)
        Utility
DT
        Granted
FS
LN.CNT 456
        INCLM: 514/724.000
INCL
        INCLS: 514/729.000
               514/724.000
NCL
        NCLM:
        NCLS:
               514/729.000
IC
        [6]
        ICM: A61K031-045
        514/724; 514/729
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 37 OF 128 USPATFULL on STN ...
L4
        1999:146556 USPATFULL
AN
        Advanced glycation end-product intermediaries and post-amadori
TI
        inhibition
        Hudson, Billy G., Omaha Park, AR, United States
IN
        Todd, Parvin, Kansas City, KS, United States
        Khalifah, Raja Gabriel, Overland Park, KS, United States
        Booth, Aaron Ashley, Kansas City, KS, United States
Kansas University Medical Center, Kansas City, KS, United States (U.S.
PA
```

corporation)

```
us 1996-711555
                                 19960910 (8)
AΤ
                             19950912 (60)
       US 1995-3628P
PRAI
       Utility
DT
       Granted
FS
LN.CNT 1804
       INCLM: 514/089.000
INCL -
                             514/351.000; 514/247.000; 514/256.000; 514/276.000;
               514/345.000;
       INCLS:
               514/023.000; 514/025.000
               514/089.000
NCL
       NCLM:
               514/023.000; 514/025.000; 514/247.000; 514/256.000; 514/276.000;
       NCLS:
               514/345.000; 514/351.000
       [6]
IC
       ICM: A61K031-00
       514/2; 514/89; 514/345; 514/351; 514/247; 514/256; 514/276; 514/23; 514/25
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 38 OF 128 USPATFULL ON STN
L4
AN
       1999:141898 USPATFULL
       Peptidyl compounds and their therapeutic use
TI
       Baxter, Andrew Douglas, Cambridge, United Kingdom
IN
       Montana, John, Cambridge, United Kingdom
       Owen, David Alan, Cambridge, United Kingdom
Darwin Discovery Limited, United Kingdom (non-U.S. corporation)
PA
                                 19991109
PΙ
       us 5981491
       wo 9635711
                    19961114
       us 1997-776630
                                 19970407 (8)
ΑI
                                 19960510
       wo 1996-GB1136
                                 19970407
                                            PCT 371 date
                                 19970407
                                            PCT 102(e) date
                             19950510
       GB 1995-9403
PRAI
       GB 1995-9816
                             19950510
       GB 1996-7155
                             19960404
       GB 1996-7215
                             19960404
       Utility
DT
        Granted
LN.CNT 1445
        INCLM: 514/019.000
INCL
               514/018.000; 424/184.100; 424/185.100; 530/331.000; 530/868.000;
        INCLS:
               260/998.200
               514/019.000
       NCLM:
NCL
               260/998.200; 424/184.100; 424/185.100; 514/018.000; 530/331.000;
       NCLS:
               530/868.000
IC
        [6]
        ICM: A61K038-05
        ICS: A61K045-05
        514/18; 514/19; 530/331; 530/868; 260/998.2; 424/184.1; 424/185.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 39 OF 128 USPATFULL ON STN
        1999:141601 USPATFULL
AN
        Use of p97 and iron binding proteins as diagnostic and therapeutic
ΤI
        Jefferies, Wilfred A., South Surrey, Canada
IN
        McGeer, Patrick L., Vancouver, Canada
       Rothenberger, Sylvia, Epalinges, Switzerland Food, Michael R., Vancouver, Canada
        Yamada, Tatsuo, Tokyo, Japan
        Kennard, Malcolm, Vancouver, Canada
        University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PA
                                  19991109
        us 5981194
PΙ
        us 1995-520933
                                  19950831 (8)
ΑI
        Continuation-in-part of Ser. No. US 367224
RLI
DT
        Utility
FS
        Granted
LN.CNT
       5517
        INCLM: 435/007.100
INCL
        INCLS: 530/387.100
NCL
        NCLM:
               435/007.100
        NCLS:
               530/387.100
IC
        [6]
        ICM: G01N033-53
        ICS: C07K016-00
        435/7.1; 530/387.1
FXF
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 40 OF 128 USPATFULL ON STN
L4
        1999:141575 USPATFULL
AN
        Method and composition for modulating amyloidosis
TI
        Reiner, Peter B., Vancouver, Canada
Connop, Bruce P., Vancouver, Canada
The University of British Columbia, Vancouver, Canada (non-U.S.
IN
PA
        corporation)
PΙ
        us 5981168
                                      19991109
                                      19980515 (9)
        US 1998-80141
ΑI
DT
        Utility
        Granted
FS
LN.CNT 1184
        INCLM: 435/004.000
INCL
        INCLS: 435/029.000; 514/639.000; 514/638.000; 514/600.000; 514/601.000; 514/395.000; 514/310.000; 514/255.000
                 435/004.000
NCL
        NCLM:
                 435/029.000; 514/255.060; 514/310.000; 514/395.000; 514/600.000;
        NCLS:
                 514/601.000; 514/638.000; 514/639.000
IC
         [6]
        ICM: C12Q001-00
        435/4; 435/29; 514/639; 514/638; 514/600; 514/601; 514/395; 514/310;
FXF
        514/255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 41 OF 128 USPATFULL ON STN
         1999:137223 USPATFULL
AN
         Inhibitors of . ***beta*** .- ***amyloid***
                                                                      protein production
ΤI
        Cordell, Barbara, Palo Alto, CA, United States
IN
        Schirlin, Daniel, Lampertheim, France
Peet, Norton P., Cincinnati, OH, United States
Higaki, Jeffrey N., Mountain View, CA, United States
        Van Dorsselaer, Viviane, Strasbourg, France
        Angelastro, Michael R., Cincinnati, OH, United States
PA
        Merrell Pharmaceuticals, Inc., Bridgewater, NJ, United States (U.S.
        corporation)
        us 5977074
                                       19991102
PΙ
                                                                                     <---
                       19950413
        wo 9509838
        US 1996-624407
                                       19960328 (8)
AI
        wo 1994-US10679
                                       19940920
                                       19960328
                                                   PCT 371 date
                                                  PCT 102(e) date
                                       19960328
PRAI
        EP 1993-402398
                                  19931001
DT
        Utility
FS
        Granted
LN.CNT 2745
        INCLM: 514/019.000
INCL
        INCLS: 514/357.000; 546/145.000; 546/170.000; 546/335.000; 546/337.000; 560/027.000; 564/157.000; 564/158.000; 564/165.000; 549/044.000;
                  544/162.000; 544/168.000
                 514/019.000
NCL
        NCLM:
                 514/357.000; 544/162.000; 544/168.000; 546/145.000; 546/170.000; 546/335.000; 546/337.000; 549/044.000; 560/027.000; 564/157.000; 564/158.000; 564/165.000
        NCLS:
IC
         [6]
         ICM: A61K038-05
         ICS: C07K001-00
         514/19; 514/357; 546/145; 546/170; 546/335; 546/337; 560/27; 564/157;
EXF
         564/158; 564/165; 549/44; 544/162; 544/168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 42 OF 128 USPATFULL on STN
        1999:136965 USPATFULL
Cell tests for alzheimer's disease
ΑN
TI
        Alkon, Daniel L., Bethesda, MD, United States
IN
        Etcheberrigaray, Rene, Rockville, MD, United States
Kim, Christopher S., Silver Spring, MD, United States
        Han, Yi-Fan, Shanghai, China
        Nelson, Tom J., Silver Spring, MD, United States
        The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PA
        US 5976816
                                       19991102
PΙ
        US 1994-312202
                                       19940926 (8)
ΑI
        Continuation-in-part of Ser. No. US 1993-56456, filed on 3 May 1993, now
RLI
        patented, Pat. No. US 5580748
DT
        Utility
```

```
LN.CNT 1994
       INCLM: 435/007.210
INCL
       INCLS: 435/007.100; 435/007.920; 530/387.100; 530/300.000; 436/548.000
       NCLM:
              435/007.210
NCL
               435/007.100; 435/007.920; 436/548.000; 530/300.000; 530/387.100
       NCLS:
       [6]
IC
       ICM: G01N033-567
       ICS: G01N033-53; C07K016-00
       435/7.1; 435/7.21; 436/547; 436/548; 436/300; 530/387.9
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 43 OF 128 USPATFULL on STN
L4
       1999:132768 USPATFULL
AN
       Method for the treatment of neurodegenerative diseases by administering
TI
       VIP, an analogue, fragment or a conjugate thereof
       Gozes, Illana, Ramat Hasharon, Israel
IN
       Fridkin, Matityahu, Rehovot, Israel
       Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S.
PA
       Ramot University Authority for Applied Research and Industrial
       Development Ltd., Tel-Aviv, Israel (non-U.S. corporation)
       US 5972883
US 1995-413708
                                  19991026
PΙ
                                  19950330 (8)
ΑI
       Continuation-in-part of Ser. No. US 1994-207671, filed on 9 Mar 1994,
RLI
       now abandoned
PRAI
       IL 1993-105061
                             19930316
       Utility
DT
FS
       Granted
LN.CNT 1190
       INCLM: 514/012.000
INCL
       INCLS: 530/324.000
               514/012.000
NCL
       NCLM:
               530/324.000
       NCLS:
        [6]
IC
        ICM: A61K038-00
       514/12; 514/879; 530/324; 530/327; 530/328
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 44 OF 128 USPATFULL on STN 1999:132587 USPATFULL
L4
ΑN
       Tryptase inhibitor
ΤI
       Fritz, Hans, Icking, Germany, Federal Republic_of
IN
       Sommerhoff, Christian, Munich, Germany, Federal Republic of
       Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PA
       UCP Gen-Pharma AG, Zurich, Switzerland (non-U.S. corporation)
       us 5972698
                                  19991026
PΙ
       wo 9503333
                     19950202
                                  19960125 (8)
       US 1996-586676
ΑI
       WO 1994-EP2445
                                  19940725
                                  19960125
                                             PCT 371 date
                                  19960125 PCT 102(e) date
                             19930726
PRAI
       EP 1993-111930
       Utility
DT
        Granted
FS
LN.CNT
       1988
        INCLM: 435/320.100
INCL
        INCLS: 435/069.200; 435/212.000; 514/012.000; 530/324.000; 536/023.500
NCL
               435/320.100
       NCLM:
               435/069.200; 435/212.000; 514/012.000; 530/324.000; 536/023.500
       NCLS:
IC
        [6]
        ICM: C07K014-815
       ICS: C12N015-11; A61K038-58 435/219; 435/69.2; 435/172.3; 435/320.1; 435/325; 435/252.3; 435/254.11; 514/2; 514/826; 530/300; 530/324; 536/23.1; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 45 OF 128 USPATFULL on STN
        1999:113605 USPATFULL
AN
                                                              or their derivatives
       Antibodies to .
                          ***beta*** .- ***amvloids***
TI
       and use thereof
       Suzuki, Nobuhiro, Tsukuba, Japan
IN
       Odaka, Asano, Tsukuba, Japan
Kitada, Chieko, Sakai, Japan
PA
       Takeda Chemical Industries, Ltd., Tokyo, Japan (non-U.S. corporation)
                                  19990921
PΙ
       us 5955317
```

```
Division of Ser. No. US 302808
RLI
                                19930125
PRAI
        JP 1993-10132
        JP 1993-19035
                                19930205
        JP 1993-286935
                                19931116
        JP 1993-334733
                                19931228
        Utility
DT
        Granted
FS
LN.CNT 2575
        INCLM: 435/070.210
INCL
        INCLS: 435/331.000; 530/387.900; 530/388.100
NCL
                435/070.210
                435/331.000; 530/387.900; 530/388.100
IC
        [6]
        ICM: C12D021-04
        ICS: C07K016-00
        435/70.21; 435/325; 435/326; 435/331; 530/387.1; 530/387.9; 530/388.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 46 OF 128 USPATFULL ON STN
AN
        1999:102423 USPATFULL
        Method for making non-crosslinked protein particles for therapeutic and
TI
        diagnostic use
        Yen, Richard C. K., Glendora, CA, United States
Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
IN
PA
                                     19990831
PI
        us `5945033
        US 1996-747137
                                     19961112 (8)
ΑI
        Continuation of Ser. No. US 1994-212546, filed on 14 Mar 1994, now
RLI
        patented, Pat. No. US 5616311 which is a continuation-in-part of Ser.
        No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US
        1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15
        Jan 1991, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 3655
        INCLM: 252/314.000
INCL
        INCLS: 424/001.290; 424/499.000; 252/302.000; 428/402.000; 428/402.240;
                 427/213.300; 427/213.330; 427/213.310
                 516/077.000
NCL
        NCLM:
                424/001.290; 424/499.000; 427/213.300; 427/213.310; 427/213.330; 428/402.000; 428/402.240
        NCLS:
         [6]
IC
         ICM: B01J013-00
         ICS: A61K009-50; B32B005-16
        424/499; 424/1.29; 424/1.37; 424/489; 424/491; 264/4.3; 264/4; 264/4.1; 264/5; 427/213.33; 427/213; 427/213.31; 428/402.2; 428/402.24; 428/402; 514/832; 514/965; 435/177; 252/302; 252/314
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 47 OF 128 USPATFULL on STN
         1999:99655 USPATFULL
AN
TI
         Furan nitrone compounds
         Kelleher, Judith A., Fremont, CA, United States
ΙN
        Maples, Kirk R., San Jose, CA, United States
        Waterbury, Lowell David, San Carlos, CA, United States Wilcox, Allan L., Mountain View, CA, United States
        Xu, Hong, Cupertino, CA, United States
         Zhang, Yong-Kang, Santa Clara, CA, United States
        Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.
PA
         corporation)
PΙ
        us 5942507
                                     19990824
                                                                                 <--
                                     19970717 (8)
         us 1997-895968
ΑI
PRAI
                                19960719 (60)
         US 1996-22169P
DT
         Utility
FS
         Granted
LN.CNT 2103
INCL
         INCLM: 514/231.500
         INCLS: 514/255.000; 514/471.000; 514/473.000; 544/152.000; 544/374.000;
                 549/475.000; 549/476.000
NCL
         NCLM:
                 514/231.500
                 514/252.010; 514/254.100; 514/471.000; 514/473.000; 544/152.000; 544/374.000; 549/475.000; 549/476.000
         NCLS:
IC
         [6]
         ICM: C07D307-52
```

ICS: C07D405-12; C07D413-12; A61K031-34

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 48 OF 128 USPATFULL ON STN
L4
         1999:99548 USPATFULL
AN
         Assays for detecting .beta.-secretase
TI
         Anderson, John P., San Francisco, CA, United States
IN
         Jacobson-Croak, Kirsten L., San Bruno, CA, United States
         Sinha, Sukanto, San Francisco, CA, United States
         Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
         corporation)
         us 5942400
                                        19990824
PΙ
                                        19960607 (8)
         us 1996-659984
ΑI
         Continuation-in-part of Ser. No. US 1995-485152, filed on 7 Jun 1995 And
RLI
         a continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995,
         now patented, Pat. No. US 5744346
         Utility
DT
         Granted
FS
LN.CNT 2312
         INCLM: 435/007.100
INCL
         INCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
                  435/007.100
NCL
                  435/023.000; 435/961.000; 436/063.000; 436/161.000
         NCLS:
         [6]
IC
         ICM: G01N033-53
         435/7.1; 435/7.2; 435/23; 435/325; 435/961; 436/515; 436/516; 436/161;
EXF
         436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 49 OF 128 USPATFULL ON STN
L4
         1999:92643 USPATFULL
AN
         Compositions and methods for stimulating
                                                                ***amvloid***
TI
         amyloidogenic diseases using advanced glycosylation endproducts
         Vitek, Michael P., East Norwich, NY, United States Cerami, Anthony, Shelter Island, NY, United States Bucala, Richard J., New York, NY, United States Ulrich, Peter C., Old Tappan, NJ, United States Vlassara, Helen, Shelter Island, NJ, United States
IN
         Zhang, Xini, Jericho, NJ, United_States
         The Picower Institute For Medical Research, Manhasset, NY, United States
PA
          (U.S. corporation)
         us 5935927
                                         19990810
PΙ
         wo 9520979
                         19950810
         US 1996-501127
                                         19960810 (8)
ΑI
                                         19950202
         WO 1995-US1380
                                         19960810
                                                      PCT 371 date
                                         19960810 PCT 102(e) date
         Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US
RLI
          1994-191579, filed on 3 Feb 1994, now abandoned
          Utility
DT
          Granted
FS
LN.CNT 2154
          INCLM: 514/012.000
 INCL
         INCLS: 514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000; 514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000; 514/647.000; 548/100.000; 548/121.000; 548/122.000; 530/300.000; 530/322.000; 536/001.110
                   514/012.000
NCL
          NCLM:
                   514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000;
          NCLS:
                   514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000; 514/647.000; 530/300.000; 530/322.000; 536/001.110; 548/100.000;
                   548/121.000; 548/122.000
 IC
          T61
          ICM: A61K038-00
          ICS: A61K031-135; A61K031-70
          530/300; 530/322; 514/2; 514/647; 514/12; 514/23; 514/569; 514/663; 514/665; 514/79; 514/91; 514/95; 514/359; 514/438; 514/439; 514/443; 514/642; 548/100; 548/121; 548/122; 536/1.11
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L4
       ANSWER 50 OF 128 USPATFULL ON STN
          1999:92571 USPATFULL
 AN
                                         protein precursor homolog and kunitz-type
                    ***amvloid***
          Human
 TI
          inhibitor
```

Sprecher, Cindy A., Seattle, WA, United States

IN

```
Norris, Kjeld E., Hellerup, Denmark
       ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PA
                                   19990810
       us 5935854
PΙ
                                  19950418 (8)
       us 1995-424017
ΑI
       Division of Ser. No. US 1993-155331, filed on 19 Nov 1993, now patented,
RLI
       Pat. No. US 5441931 which is a continuation-in-part of Ser. No. US
       1992-985692, filed on 2 Dec 1992, now patented, Pat. No. US 5436153
       Utility
DT
        Granted
FS
       1725
LN.CNT
        INCLM: 435/331.000
INCL
        INCLS: 530/387.900; 530/388.100
               435/331.000
NCL
               530/387.900; 530/388.100
        NCLS:
        [6]
IC
        ICM: C12N005-00
        530/387.9; 530/388.1; 530/388.24; 435/240.26; 435/326; 435/331; 435/335
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 51 OF 128 USPATFULL ON STN
L4
        1999:89052 USPATFULL
ΑN
        Human nucleolin-like protein
TI
        Bandman, Olga, Mountain View, CA, United States
IN
        Yue, Henry, Sunnyvale, CA, United States
        Corley, Neil C., Mountain View, CA, United States
        Shah, Purvi, Sunnyvale, CA, United States
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
                                   19990803
                                                                             <--
        us 5932475
PI
        US 1997-990114
                                   19971212 (8)
ΑI
        Utility
DΤ
FS
        Granted
LN.CNT 2215
        INCLM: 435/320.100
INCL
        INCLS: 530/350.000; 536/023.100; 536/023.500; 435/069.100; 435/006.000
                435/320.100
NCL
        NCLM:
                435/006.000; 435/069.100; 530/350.000; 536/023.100; 536/023.500
        NCLS:
IC
        [6]
        ICM: C12N015-00
        530/350; 536/23.1; 536/23.5; 435/320.1; 435/69.1; 435/6
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 52 OF 128 USPATFULL on STN
L4
        1999:85445 USPATFULL
ΑN
        Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
TI
        Durette, Philippe, New Providence, NJ, United States
TN
        Kopka, Ihor, Millburn, NJ, United States
        MacCoss, Malcolm, Freehold, NJ, United States
        Mills, Sander, Scotch Plains, NJ, United States
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
US 5929094 19990727 <--
PA
PΙ
        US 1997-956181
                                   19971022 (8)
ΑI
        Utility
DT
        Granted
FS
LN.CNT 3849
        INCLM: 514/340.000
INCL
        INCLS: 546/268.400; 546/272.400; 548/217.000; 548/304.700; 548/466.000;
                549/462.000
                514/340.000
NCL
        NCLM:
                546/268.400; 546/272.400; 548/217.000; 548/304.700; 548/466.000;
        NCLS:
                549/462.000
TC
        [6]
        ICM: A61K031-44
        ICS: C07D405-14
        546/268.4; 546/272.4; 546/271.7; 546/273.7; 546/274.1; 546/277.4; 546/284.4; 514/340; 514/341; 514/338; 514/339; 548/304.7; 548/217;
EXF
        546/284.4;
        548/466; 549/462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 53 OF 128 USPATFULL ON STN
14
AN
        1999:78711 USPATFULL
        Morpholine and thiomorpholine tachykinin receptor antagonists
TI
        Dorn, Conrad P., Plainfield, NJ, United States Hale, Jeffrey J., Westfield, NJ, United States Maccoss. Malcolm. Freehold, NJ, United States
IN
```

```
Shah, Shrenik K., Metuchen, NJ, United States
              Ladduwahetty, Tamara, Buckhurst Hill, United Kingdom
              Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
                                                              19990713
              us 5922706
PΙ
              US 1997-969685 19971113 (8)
Division of Ser. No. US 1995-525259, filed on 5 Sep 1995, now patented,
ΑI
RLI
              Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO
              1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-169889, filed on
              17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No.
              US 1993-61914, filed on 19 May 1993, now abandoned which is a
              continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US
              1992-905976, filed on 29 Jun 1992, now abandoned
DT
              Utility
              Granted
FS
LN.CNT 7932
              INCLM: 514/227.500 INCLS: 514/227.800;
INCL
                                                     514/228.200; 514/231.200; 514/231.500; 514/233.500;
                                                      514/235.200; 514/235.800; 514/236.200; 514/236.500;
                            514/233.800;
                            514/236.800; 514/237.200; 544/059.000; 544/060.000; 544/062.000;
                            544/058.100; 544/058.400; 544/106.000; 544/111.000; 544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000; 514/227.500
514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500; 514/233.800; 514/233.800; 514/233.800; 514/235.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/236.800; 514/23
                                                                                                                                    544/114.000;
                                                                                                                                     544/143.000;
NCL
              NCLM:
                                                      514/228.200; 514/231.200; 514/231.500; 514/233.500;
              NCLS:
                                                      514/235.200; 514/235.800; 514/236.200; 514/236.500;
                            514/233.800;
                                                      514/237.200; 544/058.100; 544/058.400; 544/059.000;
                            514/236.800;
                            544/060.000; 544/062.000; 544/106.000; 544/111.000; 544/114.000;
                            544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000
IC
               [6]
              ICM: C07D413-04
               ICS: C07D417-04; C07D279-12; C07D265-30; A61K031-54; A61K031-535
              544/59-62; 544/58.1; 544/58.4; 544/106; 544/111; 544/114; 544/122; 544/128-153; 514/227.5; 514/227.8; 514/228.2; 514/228.5; 514/236.2; 514/236.5; 514/233.8; 514/233.5; 514/231.2; 514/231.5; 514/236.8; 514/235.8; 514/237.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 54 OF 128 USPATFULL ON STN 1999:69704 USPATFULL
L4
 ΑN
              Human Kunitz-type inhibitors and compositions thereof
 TI
              Sprecher, Cindy A., Seattle, WA, United States
 IN
               Kisiel, Walt, Albuquerque, NM, United States
               Foster, Donald C., Seattle, WA, United States
              Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation) University of New Mexico, Albuquerque, NM, United States (U.S.
 PA
               corporation)
 PΙ
               us 5914315
                                                               19990622
              US 1995-457887
                                                               19950601 (8)
 ΑI
              Division of Ser. No. US 1993-147710, filed on 5 Nov 1993, now patented,
 RLI
               Pat. No. US 5455338
 DT
              Utility
               Granted
 FS
 LN.CNT 1623
               INCLM: 514/012.000
 INCL
               INCLS: 530/350.000; 530/381.000; 530/384.000
                             514/012.000
 NCL :
               NCLM:
               NCLS:
                            530/350.000; 530/381.000; 530/384.000
 IC
               [6]
               ICM: A61K038-36
               ICS: C07K014-745
               514/12; 530/350; 530/381; 530/384
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 55 OF 128 USPATFULL ON STN
 L4
               1999:67429 USPATFULL
 ΑN
                                                                                                     ***amyloid*** -forming
               Transgenic non-human mice displaying the
 TI
               pathology of alzheimer's disease
               Cordell, Barbara, Palo Alto, CA, United States
 IN
               Scios Inc., Mountain View, CA, United States (U.S. corporation)
US 5912410 19990615 <-
 PA
 PΙ
               US 1995-422333
                                                               19950413 (8)
```

ΑI

```
abandoned which is a continuation-in-part of Ser. No. US 1991-716725,
       filed on 17 Jun 1991, now patented, Pat. No. US 5387742 which is a
       continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 2702
        INCLM: 800/002.000
INCL
       INCLS: 800/DIG.001; 424/009.200; 935/062.000
               800/012.000
NCL
              424/009.200
       NCLS:
        [6]
IC
        ICM: C12N015-00
        ICS: C12N005-00; A61K049-00
       800/2; 800/DIG.1; 935/62; 424/9.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 56 OF 128 USPATFULL ON STN
L4
        1999:67147 USPATFULL
ΑN
TI
       Human ena/VASP-like protein splice variant
IN
        Lal, Preeti, Santa Clara, CA, United States
        Guegler, Karl J., Menlo Park, CA, United States
        Corley, Neil C., Mountain View, CA, United States
        Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
                                  19990615
PI
        US 5912128
       US 1998-26587
                                  19980220 (9)
ΑI
       Utility
DT
FS
        Granted
LN.CNT 2447
        INCLM: 435/006.000
INCL
        INCLS: 435/069.100; 435/091.200; 435/320.100; 435/252.300; 436/094.000; 530/350.000; 536/023.500
        NCLM:
               435/006.000
NCL
               435/069.100; 435/091.200; 435/252.300; 435/320.100; 436/094.000;
        NCLS:
               530/350.000; 536/023.500
IC
        [6]
        ICM: C12N015-12
        ICS: C12N015-63; C12N015-70; C12P019-34
435/6; 435/69.1; 435/91.2; 435/320.1; 435/252.3; 436/94; 530/350;
EXF
        536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 57 OF 128 USPATFULL ON STN
AN
        1999:53572 USPATFULL
TI
        Correction of genetic defects using chemical chaperones
       Welch, William J., 48 Fountain, San Francisco, CA, United States 94114
IN
        Brown, C. Randell, 1470 9th Ave. #12, San Francisco, CA, United States
        94122
        Tatzelt, Jorg, 740 Parnassus, San Francisco, CA, United States 94122
        us 5900360
                                  19990504
PΙ
        US 1997-838691
                                  19970409 (8)
ΑI
        US 1996-15155P
                             19960410 (60)
PRAI
DT
        Utility
FS
        Granted
LN.CNT 2062
INCL
        INCLM: 435/029.000
        INCLS: 435/004.000; 435/005.000; 435/034.000; 436/063.000; 436/086.000; 436/506.000; 436/811.000
        NCLM:
               435/029.000
NCL
        NCLS:
               435/004.000; 435/005.000; 435/034.000; 436/063.000; 436/086.000;
               436/506.000; 436/811.000
        [6]
IC
        ICM: C12Q001-02
        ICS: C12Q001-04; G01N033-48; G01N033-564 435/29; 435/34; 435/4; 435/5; 436/86; 436/63; 436/811; 436/506
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 58 OF 128 USPATFULL ON STN
L4
        1999:43631 USPATFULL
AN
        Use of [R-(Z)]-.alpha.-(methoxyimino)-.alpha.-(1-azabicyclo
TI
        [2.2.2.]oct-3-yl)acetonitrile to reduce
                                                     ***amyloid***
                                                                       .beta.A4
        formation in alzheimer's disease
Markwell, Roger Edward, SmithKline Beecham Corporation Corporate
IN
        Intellectual Property--UW2220 P.O. Box 1539, King of Prussia, PA, United
```

```
Hawkins, Julie, SmithKline Beecham Corporation Corporate Intellectual
        Property--UW2220 P.O. Box 1539, King of Prussia, PA, United States
        Gray, Carol Wendy, SmithKline Beecham Corporation Corporate Intellectual
        Property--UW2220 P.O. Box 1539, King of Prussia, PA, United States
        19406-0939
                                     19990406
        US 5891887
PΙ
        wo 9612486
                     19960502
        US 1997-836013
                                     19970425 (8)
ΑI
                                     19951017
        WO 1995-EP4082
                                     19970425
                                                 PCT 371 date
                                     19970425 PCT 102(e) date
                                19941025
        GB 1994-21472
PRAI
DT
        Utility
        Granted
FS
LN.CNT 511
        INCLM: 514/299.000
INCL
        NCLM: 514/299.000
NCL
IC
        [6]
        ICM: A61K031-435
        514/299
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 59 OF 128 USPATFULL ON STN
L4
        1999:37165 USPATFULL
AN
TI
        Methods and compositions for the treatment of neurodegeneration
        Bergeron, Jr., Raymond J., Gainesville, FL, United States
IN
        Borg, Stefan, Ponte Vedra Beach, FL, United States
University Of Florida Research Foundation, Inc., Gainesville, FL, United
PA
        States (U.S. corporation)
        SunPharm Corporation, Jacksonville, FL, United States (U.S. corporation)
        US 5886051
                                     19990323
PΙ
                                     19951108 (8)
        us 1995-554370
ΑI
        Utility
DT
FS
        Granted
LN.CNT 1000
        INCLM: 514/662.000
INCL
        INCLS: 514/660.000; 514/674.000; 514/654.000; 514/316.000; 514/315.000
NCL
                 514/662.000
                 514/315.000; 514/316.000; 514/654.000; 514/660.000; 514/674.000
        NCLS:
IC
        [6]
        ICM: A61K031-13
         ICS: A61K031-445
         514/674; 514/649; 514/651; 514/654; 514/655; 514/656; 514/657; 514/659;
EXF
         514/667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 60 OF 128 USPATFULL on STN
        1999:27650 USPATFULL
ΑN
        Phenyl spiroethercycloalkyl tachykinin receptor antagonists
TI
        Caldwell, Charles G., Scotch Plains, NJ, United States
IN
        Chiang, Yuan-Ching, East Lyme, CT, United States
Dorn, Conrad, Plainfield, NJ, United States
        Finke, Paul, Milltown, NJ, United States
        Hale, Jeffrey, Westfield, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States
        Mills, Sander, Scotch Plains, NJ, United States
        Robichaud, Albert, Landenberg, PA, United States
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
        US 5877191
                                      19990302
PΙ
ΑI
        US 1997-955898
                                     19971022 (8)
        Utility
DT
FS
        Granted
LN.CNT 6950
INCL
        INCLM: 514/337.000
                 514/381.000; 514/465.000; 548/127.000; 548/128.000; 548/134.000; 548/136.000; 548/250.000; 548/253.000; 548/255.000; 548/262.200; 548/950.000; 549/345.000
                 514/337.000
NCL
        NCLM:
                 514/381.000; 514/465.000; 548/127.000; 548/128.000; 548/134.000; 548/136.000; 548/250.000; 548/253.000; 548/255.000; 548/262.200; 548/950.000; 549/345.000
        NCLS:
IC
         [6]
        ICM: A61K031-36
```

ICS: C07D285-04; C07D307-94; C07D311-96

```
548/262.2; 548/950; 549/345; 514/337; 514/381; 514/465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 61 OF 128 USPATFULL ON STN
L4
        1999:27476 USPATFULL
ΑN
        APP770 mutant in alzheimer's disease
TI
        Hardy, John Anthony, Tampa, FL, United States
Chartier-Harlin, Marie-Christine, Villeneuve d'Ascq, France
IN
        Goate, Alison Mary, Michael, MO, United States
        Owen, Michael John, South Glamorgan, Scotland
        Mullan, Michael John, Tampa, FL, United States
        Imperial College of Science, Technology of Medicine, London, England
PA
        (non-U.S. corporation)
                                    19990302
        us 5877015
PΙ
                                                                                <--
        wo 9213069
                      19920806
                                                                                <--
        us 1992-104165
                                    19920121 (8)
ΑT
        wo 1992-GB123
                                    19920121
                                                PCT 371 date
                                    19940121
                                    19940121 PCT 102(e) date
PRAT
        GB 1991-1307
                               19910121
        GB 1991-18445
                               19910828
        Utility
DT
        Granted
FS
LN.CNT 1734
        INCLM: 435/325.000
INCLS: 435/252.300; 536/023.500
INCL
               435/325.000
NCL
        NCLM:
        NCLS:
               435/252.300; 536/023.500
        [6]
IC
        ICM: C12N005-10
        ICS: C12N001-21; C07H021-04
        435/29; 435/240.1; 435/252.3; 435/6; 435/325; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 62 OF 128 USPATFULL on STN
AN
        1999:22097 USPATFULL
TI
        Morpholine and thiomorpholine tachykinin receptor antagonists
IN
        Dorn, Conrad P., Plainfield, NJ, United States
        Finke, Paul E., Milltown, NJ, United States
        Hale, Jeffrey J., Westfield, NJ, United States Maccoss, Malcolm, Freehold, NJ, United States
        Mills, Sander G., Woodbridge, NJ, United States
Shah, Shrenik K., Metuchen, NJ, United States
        Chambers, Mark Stuart, Watford, England
        Harrison, Timothy, Great Dunmow, England
        Ladduwahetty, Tamara, Buckhurst Hill, England
        Williams, Brian John, Great Dunnow, England
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) US 5872116 19990216 <-
PA
PΙ
        us 1997-959393
        US 1997-959393 19971028 (8)
Division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented,
ΑI
RLI
        Pat. No. US 5719147 And a continuation-in-part of Ser. No. US
        1993-169889, filed on 17 Dec 1993, now abandoned which is a
        continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993,
        now abandoned which is a continuation-in-part of Ser. No. US
        1992-971448, filed on 4 Nov 1992, now abandoned which is a
        continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
        now abandoned
        Utility
DT
        Granted
FS
LN.CNT 8249
INCL
        INCLM: 514/227.500
        INCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;
                514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;
                514/825.000
NCL
        NCLM:
                514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000; 514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;
        NCLS:
                514/825.000
IC
        [6]
        ICM: A61K031-54
        ICS: A61K031-535; A61K031-53; A61K031-50
EXF 514/227.5; 514/227.8; 514/231.2; 514/231.5; 514/241; 514/247; 514/361; 514/362; 514/363; 514/378; 514/397; 514/825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 63 OF 128 USPATFULL ON STN
L4
ΑN
       1999:19160 USPATFULL
       Spiro-substituted azacycles as tachykinin receptor antagonists
ΤI
       Hale, Jeffrey J., Westfield, NJ, United States
IN
       Maccoss, Malcolm, Freehold, NJ, United States
       Mills, Sander G., Woodbridge, NJ, United States
       Qi, Hongbo, Edison, NJ, United States
       Shah, Shrenik K., Metuchen, NJ, United States
       Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
                                  19990209
       us 5869496
PΙ
       wo 9417045
                    19940804
                                                                          <--
                                  19950711 (8)
       us 1995-481418
ΑI
                                  19940125
       wo 1994-US819
                                            PCT 371 date
                                  19950711
                                  19950711
                                            PCT 102(e) date
DT
       Utility
       Granted
FS
LN.CNT 1976
       INCLM: 514/278.000
INCL
       INCLS: 546/017.000; 546/018.000; 546/019.000
               514/278.000
NCL
               546/017.000; 546/018.000; 546/019.000
       NCLS:
IC
        [6]
       ICM: C07D471-00
       ICS: C07D487-00; A61K031-445 546/18; 546/17; 514/278
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 64 OF 128 USPATFULL ON STN
L4
        1999:19153 USPATFULL
AN
TI
       Trypthophan ureas as neurokinnin antagonists
       Shah, Shrenik K., Metuchen, NJ, United States
Qi, Hongbo, Edison, NJ, United States
IN
       Maccoss, Malcolm, Freehold, NJ, United States
       Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) US 5869489 19990209 <-
PA
ΡI
ΑI
        us 1997-814387
                                  19970311 (8)
DT
        Utility
        Granted
FS
LN.CNT 1140
INCL
        INCLM:
               514/253.000
               514/259.000; 514/278.000; 514/323.000; 544/284.000; 544/373.000;
        INCLS:
               546/017.000; 546/201.000
               514/254.090
NCL
       NCLM:
               514/266.220; 514/278.000; 514/323.000; 544/284.000; 544/373.000;
        NCLS:
               546/017.000; 546/201.000
        [6]
IC
        ICM: A61K031-495
        ICS: C07D401-12; C07D403-12; C07D471-10 546/17; 546/201; 544/284; 544/373; 514/253; 514/259; 514/278; 514/323
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 65 OF 128 USPATFULL ON STN
L4
        1999:13026 USPATFULL
ΑN
        Antibodies to advanced glycosylation end-product receptor polypeptides
TI
        and uses therefor
        Morser, Michael John, San Francisco, CA, United States
IN
        Nagashima, Mariko, Belmont, CA, United States
        Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of
PA
        (non-U.S. corporation)
PT
        us 5864018
                                  19990126
                                                                          <--
ΑI
        us 1996-633148
                                  19960416 (8)
        Utility
DT
        Granted
FS
LN.CNT 1960
        INCLM: 530/387.100
INCL
        INCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300
               530/387.100
NCL
        NCI M:
        NCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300
IC
        ICM: C07K016-00
        530/387.1; 530/387.3; 530/388.1; 530/388.225; 530/391.3
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 66 OF 128 USPATFULL ON STN

```
.beta. APP-C100 receptor
TI
         Manly, Susan P., Wallingford, CT, United States
ΙN
         Kozlowski, Michael R., Noank, CT, United States
         Neve, Rachael L., Belmont, MA, United States
         Bristol-Myers Squibb Company, New York, NY, United States (U.S.
PA
         corporation)
         McLean Hospital Corporation, Belmont, MA, United States (U.S.
         corporation)
                                       19981229
         us 5854392
PI
                                       19930830 (8)
         us 1993-114555
ΑI
         Continuation-in-part of Ser. No. US 1992-938184, filed on 31 Aug 1992,
RLI
         now abandoned
DT
         Utility
         Granted
FS
LN.CNT 1734
         INCLM: 530/350.000
INCL
                 530/327.000; 530/395.000; 435/069.100; 536/023.500
         INCLS:
                  530/350.000
         NCLM:
NCL
         NCLS:
                 435/069.100; 530/327.000; 530/395.000; 536/023.500
TC
         Γ61
         ICM: C07K014-435
         530/350; 530/395; 530/327; 435/69.1; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 67 OF 128 USPATFULL ON STN
L4
         1998:161979 USPATFULL
AN
         Preventing and reversing the formation of advanced glycosylation
ΤI
         endproducts
         Cerami, Anthony, Shelter Island, NY, United States
IN
        Ulrich, Peter C., Old Tappan, NJ, United States Wagle, Dilip R., Valley Cottage, NY, United States Hwang, San-Bao, Sudbury, MA, United States Vasan, Sara, Yonkers, NY, United States Egan, John J., Mountain Lakes, NJ, United States
         The Picower Institute for Medical Research, Manhasset, NY, United States
PA
         (U.S. corporation)
         Alteon Inc., Ramsey, NJ, United States (U.S. corporation)
                                       19981229
PΙ
         us 5853703
         US 1996-588249
                                       19960118 (8)
ΑI
         Continuation-in-part of Ser. No. US 1995-473104, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US
RLI
         1995-375155, filed on 18 Jan 1995, now patented, Pat. No. US 5656261
DT
         Utility
         Granted
FS
LN.CNT 2478
INCL
         INCLM: 424/053.000
         INCLS: 424/051.000; 424/052.000; 424/054.000; 424/056.000; 514/365.000; 514/367.000; 548/152.000; 548/161.000; 548/164.000; 548/179.000; 548/180.000; 548/190.000; 548/193.000; 548/194.000; 548/202.000; 548/203.000; 548/204.000; 548/205.000
                  424/053.000
NCL
         NCLM:
                  424/051.000; 424/052.000; 424/054.000; 424/056.000; 514/365.000;
         NCLS:
                  514/367.000; 548/152.000; 548/161.000; 548/164.000; 548/179.000; 548/180.000; 548/190.000; 548/193.000; 548/194.000; 548/202.000; 548/203.000; 548/204.000; 548/205.000
IC
         [6]
         ICM: A61K031-38
         ICS: C07D277-24
         424/53; 424/51; 424/52; 424/54; 424/56; 514/365; 514/367; 548/512;
EXF
         548/161; 548/164; 548/179; 548/180; 548/190; 548/193; 548/194; 548/202; 548/203; 548/204; 548/205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 68 OF 128 USPATFULL on STN
         1998:161900 USPATFULL
AN
         Peptidyl compounds and their therapeutic use as inhibitors of
TI
         metalloproteinases
         Montana, John, Cambridge, United Kingdom
IN
         Owen, David Alan, Cambridge, United Kingdom
         Dickens, Jonathan, Cambridge, United Kingdom
         Baxter, Andrew Douglas, Cambridge, United Kingdom
         Chiroscience Limited, United Kingdom (non-U.S. corporation)
PA
PΙ
         us 5853623
                                       19981229
                                       19960510 (8)
         US 1996-644383
ΑI
         GB 1993-23165
                                  19931110
PRAI
```

```
Granted
FS
LN.CNT 1179
       INCLM: 260/998.200
INCL
       INCLS: 260/998.210; 530/868.000; 514/019.000
               514/019.000
NCL
       NCLM:
               260/998.200; 260/998.210; 530/868.000
       NCLS:
       [6]
IC
       ICM: C07K005-062
       ICS: A61K038-55
       260/998.2; 260/998.21; 530/868; 514/2; 514/19
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 69 OF 128 USPATFULL ON STN
L4
       1998:159959 USPATFULL
AN
       Aza spiro compounds acting on the cholinergic system with muscarinic
TI
       agonist activity
       Fisher, Abraham, Holon, Israel
IN
       Karton, Yishal, Ness-Ziona, Israel
       Marciano, Daniele, Ramat-Hasharon, Israel
       Barak, Dov, Rehovot, Israel
Meshulam, Haim, Bat Yam, Israel
       Israel Institute for Biological Research, Nessziona, Israel (non-U.S.
PA
       corporation)
       us 5852029
                                 19981222
PΙ
       US 1996-627222
                                 19960118 (8)
ΑI
       Continuation-in-part of Ser. No. US 1993-94855, filed on 20 Jul 1993,
RLI
       now patented, Pat. No. US 5534520 which is a continuation-in-part of
       Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a
       continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990,
       now abandoned
       Utility
DT
FS
       Granted
LN.CNT 4189
        INCLM: 514/278.000
INCL
       INCLS: 546/016.000; 546/019.000; 546/020.000
NCL
               514/278.000
               546/016.000; 546/019.000; 546/020.000
       NCLS:
        [6]
IC
        ICM: C07D491-10
       ICS: C07D491-20; A61K031-445; A61K031-46 546/19; 546/16; 546/20; 514/278
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 70 OF 128 USPATFULL ON STN
L4
        1998:157599 USPATFULL
ΑN
       Transgenic rodents harboring APP allele having swedish mutation
TI
       McLonlogue, Lisa C., San Francisco, CA, United States
IN
       Zhao, Jun, San Diego, CA, United States
Athena Neurosciences, South San Francisco, CA, United States (U.S.
PA
        corporation)
       US 5850003
                                  19981215
PI
                                 19970122 (8)
ΑI
        us 1997-785943
        Continuation of Ser. No. US 1993-148211, filed on 1 Nov 1993, now
RLI
        patented, Pat. No. US 5612486 which is a continuation-in-part of Ser.
        No. US 1993-143697, filed on 27 Oct 1993, now patented, Pat. No. US
        5604102
DT
        Utility
        Granted
FS
       1766
LN.CNT
INCL
        INCLM: 800/002.000
        INCLS: 800/DIG.001; 935/062.000
               800/009.000
NCL
        NCLM:
               800/012.000; 800/014.000; 800/018.000
        NCLS:
IC
        [6]
        ICM: C12N005-00
        ICS: C12N015-00
        800/2; 800/DIG.1; 935/62
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 71 OF 128 USPATFULL on STN
        1998:157207 USPATFULL
ΑN
TI
       Diagnostic assays for Alzheimer's disease
       Nixon, Ralph, Arlington, MA, United States
IN
       Honda, Toshiyuki, Yokohama, Japan
PA
        The McLean Hospital Corporation, Belmont, MA, United States (U.S.
```

```
US 1993-149975
                                 19931110 (8)
ΑI
       Utility
DT
       Granted
FS
LN.CNT 960
INCL
       INCLM: 436/518.000
       INCLS: 436/528.000; 436/529.000; 436/530.000; 436/161.000; 436/811.000
               436/518.000
NCL
              436/161.000; 436/528.000; 436/529.000; 436/530.000; 436/811.000
       NCLS:
       [6]
IC
       ICM: G01N033-544
       435/7.1; 435/975; 436/518; 436/530; 436/547; 436/524; 436/528; 436/529; 436/811; 436/161; 530/350; 530/387.1; 530/387.9; 530/389.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 72 OF 128 USPATFULL on STN
L4
       1998:147262 USPATFULL
ΑN
       Nucleic acids encoding presenilin II
ΤI
       St. George-Hyslop, Peter H., Toronto, Canada
IN
       Rommens, Johanna M., Toronto, Canada
       Fraser, Paul E., Toronto, Canada
The Hospital for Sick Children, Canada (non-U.S. corporation)
PA
       HSC Research and Development Limited Partnership, Canada (non-U.S.
       corporation)
PΙ
       us 5840540
                                 19981124
       us 1997-967101
                                 19971110 (8)
ΑI
       Division of Ser. No. US 1996-592541, filed on 26 Jan 1996 which is a
RLI
       continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
       which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28
       Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
       filed on 28 Apr 1995
DT
       Utility
FS
       Granted
LN.CNT 6709
INCL
       INCLM: 435/069.100
       INCLS: 435/320.100; 435/252.300; 435/325.000; 536/023.100; 536/024.300;
               530/350.000
               435/069.100
NCL
       NCLM:
               435/252.300; 435/320.100; 435/325.000; 530/350.000; 536/023.100;
       NCLS:
               536/024.300
IC
        [6]
       ICM: C12P021-06
       ICS: C07H017-00; C07K014-00
       435/69.1; 435/320.1; 435/252.3; 435/325; 536/23.1; 536/24.3; 530/350
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 73 OF 128 USPATFULL on STN
       1998:144233 USPATFULL
ΑN
       Nucleic acids molecules encoding Caspase-8h and Caspase-8i
TI
       Hunter, John J., Cambridge, MA, United States
TN
       Shyjan, Andrew W., Nahant, MA, United States
       Wong, Grace H. W., Brookline, MA, United States
       Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
       corporation)
       US 5837837
US 1997-807200
PΙ
                                 19981117
ΑI
                                 19970227 (8)
DT
       Utility
       Granted
FS
LN.CNT
       2091
INCL
       INCLM: 536/023.100
       INCLS: 530/300.000; 530/350.000
       NCLM:
NCL
               536/023.100
       NCLS:
               530/300.000; 530/350.000
IC
        [6]
        ICM: C07H021-02
       ICS: A61K038-00; C07K001-00
       536/23.1; 530/350; 435/172.3; 435/69.1; 435/325; 424/93.2
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 74 OF 128 USPATFULL ON STN
       1998:144072 USPATFULL
AN
       Methods and compositions for the detection of soluble . ***beta***
TI
          ***amyloid***
                          peptide
       Schenk, Dale B., Pacifica, CA, United States
IN
       Schlossmacher, Michael G., Vienna, Austria
```

19981215

us 5849600

PΙ

```
Seubert, Peter A., South San Francisco, CA, United States
        Vigo-Pelfrey, Carmen, Mountain View, CA, United States
        Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S.
PA
        corporation)
        Eli Lilly and Company, Indianapolis, IN, United States (U.S.
        corporation)
        Brigham and Women's Hospital, Boston, MA. United States (U.S.
        corporation)
        us 5837672
                                    19981117
PΙ
        us 1995-456347
                                    19950601 (8)
ΑI
        Division of Ser. No. US 1995-437067, filed on 9 May 1995, now patented,
RLI
        Pat. No. US 5593846 And a continuation-in-part of Ser. No. US
        1992-911647, filed on 10 Jul 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1445
        INCLM: 514/002.000
INCL
        INCLS: 514/002.000; 514/042.000; 514/076.900; 514/222.200; 424/520.000;
                435/007.900; 435/007.200; 436/518.000; 436/811.000
NCL
        NCLM:
                514/002.000
        NCLS: 424/520.000; 435/007.200; 435/007.900; 436/518.000; 436/811.000; 514/042.000; 514/169.000; 514/222.200
IC
        [6]
        ICM: A61K031-00
        ICS: A61K038-00 435/7.9; 435/4; 435/7.8; 435/6; 435/7.1; 435/7.2; 435/7.4; 436/518; 436/547; 436/548; 436/63; 436/811; 424/9.1; 424/184.1; 424/277.1;
EXF
        424/520; 514/2; 514/42; 514/169; 514/222.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 75 OF 128 USPATFULL ON STN
L4
        1998:98980 USPATFULL
AN
           ***Amyloid***
                              precursor protein in alzheimer's disease
TI
        Mullan, Michael John, Tampa, FL, United States
IN
        Alzheimer's Institute of America, Prairie Village, KS, United States
PA
        (U.S. corporation)
        us 5795963
                                     19980818
PΙ
                                     19970313 (8)
        us 1997-815637
ΑI
        Continuation of Ser. No. US 1995-487118, filed on 7 Jun 1995, now
RLI
        abandoned which is a division of Ser. No. US 1993-94547, filed on 19 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-894211,
        filed on 4 Jun 1992, now patented, Pat. No. US 5455169, issued on 3 Oct
        1995
DT
        Utility
FS
        Granted
LN.CNT 1053
        INCLM: 530/350.000
INCL
NCL
        NCLM: 530/350.000
IC
         [6]
         ICM: C07K001-00
        530/350
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 76 OF 128 USPATFULL on STN
L4
        1998:82864 USPATFULL
ΑN
TI
        Compounds and methods for inhibiting .beta.-protein filament formation
        and neurotoxicity
        Potter, Huntington, Boston, MA, United States
IN
        President and Fellows of Harvard College, Cambridge, MA, United States
PA
         (U.S. corporation)
PΙ
        us 5780587
                                     19980714
                                                                                 <--
                                     19950406 (8)
ΑI
        us 1995-417937
        Continuation-in-part of Ser. No. US 1994-328491, filed on 25 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US
RLI
        1994-290198, filed on 15 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179574, filed on 10 Jan 1994, now patented, Pat. No. US 5506097 which is a continuation-in-part of
        Ser. No. US 1992-819361, filed on 13 Jan 1992, now patented, Pat. No. US
         5338663 which is a continuation-in-part of Ser. No. US 1990-572671,
        filed on 24 Aug 1990, now abandoned
                                19930113
PRAI
        wo 1993-us325
DT
        Utility
FS
         Granted
LN.CNT 1683
        INCLM: 530/326.000
INCL
```

```
NCLM:
               530/326.000
NCL
               530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000
       NCLS:
IC
       ICM: C07K005-00
       ICS: C07K007-00; C07K017-00
        530/326-331
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 77 OF 128 USPATFULL ON STN
       1998:82754 USPATFULL
AN
       Morpholine compounds are prodrugs useful as tachykinin receptor
TI
       antagonists
       Dorn, Conrad P., Plainfield, NJ, United States
IN
       Hale, Jeffrey J., Westfield, NJ, United States Maccoss, Malcolm, Freehold, NJ, United States Mills, Sander G., Woodbridge, NJ, United States
       Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) US 5780467 19980714 <-
PA
PΙ
       US 1997-907738
                                  19970808 (8)
ΑI
       Division of Ser. No. US 1995-525870, filed on 8 Sep 1995, now patented,
RLI
        Pat. No. US 5691336 which is a continuation-in-part of Ser. No. US
        1994-206771, filed on 4 Mar 1994, now abandoned
       Utility
ÐΤ
        Granted
FS
LN.CNT
       7260
        INCLM: 514/236.200
INCL
        INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800
NCL
               514/236.200
        NCLM:
               514/233.500; 514/235.200; 514/235.500; 514/235.800
        NCLS:
IC
        [6]
        ICM: A61K031-535
        514/235.2; 514/235.5; 514/235.8; 514/233.5; 514/236.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 78 OF 128 USPATFULL ON STN
        1998:72713 USPATFULL
AN
TI
        Bax omega protein and methods
        Bitler, Catherine Mastroni, Menlo Park, CA, United States
IN
        Bowersox, Stephen Scott, Menlo Park, CA, United States
        Crea, Roberto, San Mateo, CA, United States
        Demo, Susan Dunham, San Francisco, CA, United States
Horne, William A., San Diego, CA, United States
        Zhou, Mei, Palo Alto, CA, United States
        Neurex Corporation, Menlo Park, CA, United States (U.S. corporation)
PΑ
PΙ
        us 5770690
                                  19980623
                                  19960315 (8)
ΑI
        us 1996-616732
        Continuation-in-part of Ser. No. US 1995-495042, filed on 27 Jun 1995.
RLI
        now abandoned
DΤ
        Utility
FS
        Granted
LN.CNT 3023
INCL
        INCLM: 530/324.000
        INCLS: 530/350.000; 530/329.000
               530/324.000
NCL
        NCLS:
               530/329.000; 530/350.000
IC
        [6]
        ICM: C07K014-00
        ICS: C07K007-00
        514/44; 514/2; 514/3; 530/183; 530/300; 530/350; 530/324; 530/329;
EXF
        424/185.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 79 OF 128 USPATFULL on STN
ı 4
AN
        1998:68773 USPATFULL
        Methods of screening for compounds which inhibit soluble . ***beta***
TI
            ***amyloid***
                             peptide production
        Schlossmacher, Michael G., Vienna, Austria
IN
        Selkoe, Dennis J., Jamaica Plain, MA, United States
        Athena Neurosciences, South San Francisco, CA, United States (U.S.
PA
        corporation)
        Eli Lilly and Company, Indianapolis, IN, United States (U.S.
        corporation)
        US 5766846
US 1993-79511
PΙ
                                  19980616
                                  19930617 (8)
ΑI
        Division of Ser. No. US 1992-965972, filed on 26 Oct 1992, now abandoned
RLI
```

```
Jul 1992, now abandoned
         utility
DT
         Granted
FS
LN.CNT 1465
         INCLM: 435/006.000
INCL
         INCLS: 435/007.100; 435/007.200; 435/007.210; 435/041.000; 435/069.100;
                  435/007.920; 435/007.940
                  435/006.000
         NCLM:
NCL
                  435/007.100; 435/007.200; 435/007.210; 435/007.920; 435/007.940;
         NCLS:
                  435/041.000; 435/069.100
         [6]
IC
         ICM: G01N033-53
         435/6; 435/7.1; 435/7.2; 435/7.21; 435/29; 435/41; 435/69.1; 435/70.1;
FXF
         435/70.3; 435/7.92; 435/7.94
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 80 OF 128 USPATFULL ON STN
L4
                       USPATFULL
         1998:51625
AN
         Cycloalkyl tachykinin receptor antagonists
TI
         Caldwell, Charles G., Scotch Plains, NJ, United States
IN
         Chen, Ping, Old Bridge, NJ, United States
         Durette, Philippe L., New Providence, NJ, United States
         Finke, Paul, Milltown, NJ, United States
         Hale, Jeffrey, Westfield, NJ, United States
Holson, Edward, New York, NY, United States
Kopka, Ihor, Millburn, NJ, United States
         MacCoss, Malcolm, Freehold, NJ, United States
         Meurer, Laura, Scotch Plains, NJ, United States
         Mills, Sander G., Woodbridge, NJ, United States
         Robichaud, Albert, Stirling, NJ, United States
         Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
US 5750549 19980512 <-
PA
         us 5750549
PΙ
                                        19961015 (8)
         us 1996-730277
ΑI
         Utility
DT
FS
         Granted
LN.CNT 8611
         INCLM: 514/364.000
INCL
         INCLS: 514/381.000; 514/529.000; 514/530.000; 514/532.000; 514/619.000; 514/620.000; 514/716.000; 514/717.000; 514/730.000; 514/731.000; 548/143.000; 548/250.000; 548/251.000; 548/252.000; 548/253.000; 548/254.000; 560/038.000; 560/039.000; 560/043.000; 564/164.000; 564/163.000; 564/168.000
NCL
         NCLM:
                   514/364.000
                   514/381.000; 514/529.000; 514/530.000; 514/532.000; 514/619.000;
         NCLS:
                  514/620.000; 514/716.000; 514/717.000; 514/730.000; 514/731.000; 548/143.000; 548/250.000; 548/251.000; 548/252.000; 548/253.000; 548/254.000; 560/038.000; 560/039.000; 560/043.000; 564/164.000; 564/168.000; 568/661.000
IC
          [6]
          ICM: A61K031-41
          ICS: C07D257-04; C07D271-10
          548/143; 548/250; 548/251; 548/252; 548/253; 548/254; 560/38; 560/39; 560/43; 564/163; 564/164; 564/168; 568/647; 568/661; 514/364; 514/381
EXF
          514/529; 514/530; 514/532; 514/619; 514/620; 514/716; 514/717; 514/730;
          514/731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 81 OF 128 USPATFULL ON STN
L4
          1998:51432 USPATFULL
ΑN
                                ***beta***
                                               .- ***amvloids***
                                                                           or their derivatives
          Antibodies to
TI
          and use thereof
          Suzuki, Nobuhiro, Ibaraki, Japan
IN
          Odaka, Asano, Ibaraki, Japan
         Kitada, Chieko, Osaka, Japan
Takeda Chemical Industries Ltd., Osaka, Japan (non-U.S. corporation)
PΑ
          us 5750349
                                         19980512
PΙ
          WO 9417197
                         19940804
                                         19940915 (8)
         US 1994-302808
ΑI
                                         19940124
         WO 1994-JP89
                                         19940915
                                                      PCT 371 date
                                         19940915
                                                      PCT 102(e) date
                                    19930125
          JP 1993-10132
PRAI
          JP 1993-19035
                                    19930205
          JP 1993-286985
                                    19931116
```

19931228

JP 1993-334773

```
Granted
FS
LN.CNT 2609
        INCLM: 435/007.100
INCL
        INCLS: 435/007.920; 435/007.940; 435/007.950; 435/070.210; 435/326.000; 435/331.000; 530/387.900; 530/388.100; 530/389.100
        NCLM:
                435/007.100
NCL
                435/007.920; 435/007.940; 435/007.950; 435/070.210; 435/326.000;
        NCLS:
                435/331.000; 530/387.900; 530/388.100; 530/389.100
        [6]
IC
        ICM: G01N033-53
        435/7.1; 435/7.92; 435/7.94; 435/70.21; 435/240.27; 435/240.26; 435/7.95; 435/331; 435/326; 436/811; 530/387.9; 530/388.1; 530/389.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 82 OF 128 USPATFULL ON STN
L4
        1998:30992 USPATFULL
ΑN
        Method for treating Alzheimer's disease using glial line-derived
TI
        neurotrophic factor (GDNF) protein product
        Williams, Lawrence R., Thousand Oaks, CA, United States
IN
        Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PA
                                    19980324
        us 5731284
ΡI
        us 1995-535682
                                    19950928 (8)
ΑI
        Utility
DT
        Granted
FS
LN.CNT 1677
        INCLM: 514/008.000
INCL
        INCLS: 514/021.000
                514/008.000
        NCLM:
NCL
                514/021.000
        NCLS:
        [6]
IC
        ICM: A61F002-00
        ICS: A61K047-00; A61K031-685; A61K038-00
        514/8; 514/21
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 83 OF 128 USPATFULL ON STN
        1998:28190 USPATFULL
ΑN
        Antibodies directed against elk ligand
TI
        Lyman, Stewart, Seattle, WA, United States
IN
        Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
        Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PA
                                    19980317
        us 5728813
ΡI
        US 1996-747240
                                     19961112 (8)
ΑI
        Division of Ser. No. US 1995-460741, filed on 2 Jun 1995, now patented,
RLI
        Pat. No. US 5670625 which is a division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented, Pat. No. US 5512457 which is a continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
        now_abandoned
         Utility
DT
FS
         Granted
LN.CNT 1717
INCL
         INCLM: 530/387.900
         INCLS: 530/388.230; 424/139.100
                 530/387.900
         NCLM:
NCL
         NCLS:
                424/139.100; 530/388.230
         [6]
TC
         ICM: C07K016-24
         530/387.9; 530/388.23; 530/350; 435/69.1; 435/325; 435/331; 435/335;
EXF
         424/139.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 84 OF 128 USPATFULL ON STN
 L4
         1998:28055 USPATFULL
ΑN
         Inhibition of blood coagulation by human-kunitz-type inhibitors
 TI
         Sprecher, Cindy A., Seattle, WA, United States
 IN
         Kisiel, Walt, Albuquerque, NM, United States
         Foster, Donald C., Seattle, WA, United States
         ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 PA
                                     19980317
         us 5728674
 PΙ
                                     19950601 (8)
         us 1995-458090
 ΑI
         Division of Ser. No. US 1993-147710, filed on 5 Nov 1993, now patented,
 RLI
         Pat. No. US 5455338
 DT
         Utility
```

FS

Granted

```
INCLM: 514/002.000
INCL
       INCLS: 435/069.100; 435/172.300; 514/008.000; 530/300.000; 530/350.000
              514/002.000
       NCLM:
NCL
              435/069.100; 514/008.000; 530/300.000; 530/350.000
       NCLS:
       [6]
IC
       ICM: A61K038-16
       ICS: A61K038-17; A61K038-36
       435/69.1; 435/172.3; 435/810; 436/501; 514/2-14; 530/300; 530/350;
EXF
       935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 85 OF 128 USPATFULL ON STN
L4
       1998:24868 USPATFULL
ΑN
       Non-crosslinked protein particles for therapeutic and diagnostic use
TI
       Yen, Richard C. K., Yorba Linda, CA, United States
IN
       Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
PA
                                 19980310
PΙ
       us 5725804
       us 1995-471650
                                 19950606 (8)
ΑI
       Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994,
RLI
       now patented, Pat. No. US 5616311 which is a continuation-in-part of
       Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No.
       US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620
       which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15
       Jan 1991, now abandoned
DT
       Utility
FS
        Granted
LN.CNT 2178
INCL
        INCLM: 252/314.000
        INCLS: 252/311.000; 424/484.000; 424/491.000; 514/776.000; 514/937.000;
               514/965.000
NCL
       NCLM:
               516/077.000
               424/484.000; 424/491.000; 514/776.000; 514/937.000; 514/965.000;
       NCLS:
               516/917.000; 516/922.000
IC
        [6]
        ICM: A61K009-64
        ICS: A61K047-42; B01J013-00
        264/4.3; 427/213.3; 427/213.33; 427/2.14; 427/2.21; 514/965; 514/937;
EXF
        514/776; 252/311; 252/314; 424/491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 86 OF 128 USPATFULL ON STN
L4
        1998:19603 USPATFULL
ΑN
        Antibodies and fragments thereof which bind the carboxyl-terminus of an
TI
        amino-terminal fragment of .beta.APP
        Seubert, Peter A., South San Francisco, CA, United States
IN
        Schenk, Dale B., Pacifica, CA, United States
        Fritz, Lawrence C., San Francisco, CA, United States
        Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S.
PΑ
        corporation)
        Eli Lilly and Company, Indianapolis, IN, United States (U.S.
        corporation)
                                  19980224
        US 5721130
                                                                          <--
PΙ
                                  19950512 (8)
ΑI
        US 1995-440423
        Division of Ser. No. US 1992-965971, filed on 26 Oct 1992, now patented,
RLI
        Pat. No. US 5441870 which is a continuation-in-part of Ser. No. US 1992-868949, filed on 15 Apr 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT
       1042
INCL
        INCLM: 435/240.270
        INCLS: 435/070.210; 530/387.100; 530/387.900; 530/388.100; 530/389.100;
                530/391.100; 530/391.300
        NCLM:
NCL
               435/332.000
               435/070.210; 435/326.000; 435/331.000; 530/387.100; 530/387.900; 530/388.100; 530/389.100; 530/391.100; 530/391.300
        NCLS:
IC
        [6]
        ICM: C12N005-12
        ICS: A61K039-395
        530/387.1; 530/387.9; 530/388.1; 530/389.1; 530/391.1; 530/391.3; 435/70.21; 435/240.27; 436/547; 436/548
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 87 OF 128 USPATFULL ON STN
L4
        1998:17310 USPATFULL
ΑN
        Morpholine and thiomorpholine tachykinin receptor antagonists
TT
```

```
Finke, Paul E., Milltown, NJ, United States
              Hale, Jeffrey J., Westfield, NJ, United States
              MacCoss, Malcolm, Freehold, NJ, United States
             Mills, Sander G., Woodbridge, NJ, United States
              Shah, Shrenik K., Metuchen, NJ, United States
              Chambers, Mark Stuart, North Bushey, England
              Harrison, Timothy, Great Dunmow, England
              Ladduwahetty, Tamara, Buckhurst Hill, England
             Williams, Brian John, Great Dunnow, England
             Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) US 5719147 19980217 <-
PA
PΙ
              US 1995-525259
                                                               19950908 (8)
ΑI
              Continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914,
RLI
              filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
              now abandoned
DT
              Utility
FS
              Granted
LN.CNT 8352
              INCLM: 514/227.500
INCL
              INCLS: 514/227.800; 514/228.200; 514/233.800; 514/235.200;
                                                                                  514/231.200; 514/231.500; 514/233.500;
                                                                                  514/235.800;
                                                                                                            514/236.200;
                                                                                                                                       514/236.500;
                                                       514/237.200;
                                                                                  544/059.000; 544/060.000;
                                                                                                                                     544/061.000;
                             514/236.800;
                                                                                  544/058.400; 544/111.000; 544/106.000;
                                                       544/058.100;
                             544/062.000;
                                                      544/122.000; 544/128.000; 544/129.000; 544/132.000;
                             544/114.000:
                             544/133.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000;
                             544/143.000; 544/145.000; 544/146.000; 544/148.000; 544/152.000;
                             544/153.000
                             514/227.500
NCL
              NCLM:
                             514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500; 514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;
              NCLS:
                             514/236.800;
                                                       514/237.200; 544/058.100; 544/058.400; 544/059.000;
                             544/060.000; 544/061.000; 544/062.000; 544/106.000; 544/111.000;
                             544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000;
                             544/133.000; 544/137.000; 544/139.000
IC
               [6]
               ICM: A61K031-54
              ICS: A61K031-535; C07D413-04; C07D417-04; C07D279-12; C07D265-30 514/236.2; 514/235.5; 514/235.8; 514/236.8; 514/237.2; 514/227.5; 514/227.8; 514/228.2; 514/231.2; 514/231.5; 514/233.5; 514/233.8; 514/236.5; 544/59; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61; 544/61
EXF
              544/58.4; 544/106; 544/111; 544/114; 544/122; 544/128; 544/129; 544/132; 544/133; 544/137; 544/139; 544/140; 544/141; 544/143; 544/145; 544/146; 544/148; 544/152; 544/153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
          ANSWER 88 OF 128 USPATFULL ON STN
               1998:14789
                                      USPATFULL
AN
              Treatment of migraine with morpholine tachykinin receptor antagonists
TI
              Dorn, Conrad P., Plainfield, NJ, United States
IN
              MacCoss, Malcolm, Freehold, NJ, United States
              Hale, Jeffrey J., Westfield, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
              Merck'& Co., Inc., Rahway, Nj, United States (U.S. corporation)
US 5716942 19980210 <-
PA
PΙ
                                                               19950525 (8)
              us 1995-450198
ΑI
              Division of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
RLI
              Utility
DT
FS
              Granted
LN.CNT 6755
               INCLM: 514/090.000
INCL
               INCLS:
                             514/235.500; 514/236.200
                             514/090.000
NCL
              NCLM:
                             514/235.500; 514/236.200
              NCLS:
               [6]
IC
               ICM: A61K031-675
               ICS: A61K031-535
               514/90; 514/235.5; 514/236.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
          ANSWER 89 OF 128 USPATFULL ON STN
               1998:4424 USPATFULL
ΑN
```

Identification of phospholipase A2 inhibitors in A.beta.

TI

```
Rydel, Russell E., Belmont, CA, United States
IN
        Dappen, Michael S., San Bruno, CA, United States
        Athena Neurosciences, Inc., San Francisco, CA, United States (U.S.
PA
        corporation)
        us 5707821
                                    19980113
PΙ
                                    19950607 (8)
        us 1995-476464
ΑI
        Utility
DT
        Granted
FS
LN.CNT 1580
        INCLM: 435/018.000
INCL
        INCLS: 435/004.000; 514/012.000
                435/018.000
NCL
                435/004.000; 514/012.000
        NCLS:
IC
        [6]
        ICM: C12Q001-34
        ICS: A61K000-00
        514/12; 435/18; 435/4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 90 OF 128 USPATFULL ON STN
ΑN
        97:118191 USPATFULL
        Heterocyclic amides and methods of use
TI
        Baxter, Andrew Douglas, Cambridge, United Kingdom
IN
        Montana, John, Cambridge, United Kingdom
Owen, David Alan, Cambridge, United Kingdom
Chiroscience Limited, Cambridge, United Kingdom (non-U.S. corporation)
PA
                                    19971216
        us 5698706
PΙ
        US 1996-644802
                                    19960510 (8)
ΑI
                               19950510
        GB 1995-9432
PRAI
        GB 1995-25644
                               19951215
        GB 1996-7256
                               19960404
        Utility
DT
FS
        Granted
LN.CNT 1211
        INCLM: 548/314.700
INCL
        INCLS: 514/397.000
NCL
        NCLM: 548/314.700
IC
        [6]
        ĪCM: C07D403-02
        ICS: A61K031-415
        548/314.7; 514/396; 514/397
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 91 OF 128 USPATFULL ON STN
L4
AN
        97:109895 USPATFULL
        Morpholine compounds are prodrugs useful as tachykinin receptor
TI
        antagonists
        Dorn, Conrad P., Plainfield, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States
ΙN
        Mills, Sander G., Woodbridge, NJ, United States
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
US 5691336 19971125 <-
PA
PΙ
                                     19950908 (8)
        us 1995-525870
ΑI
        Continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994,
RLI
        now abandoned
DT
        Utility
FS
         Granted
LN.CNT 7292
        INCLM: 514/236.200
INCL
        INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000;
                 544/134.000; 544/139.000; 544/141.000; 544/143.000
                 514/236.200
        NCLM:
NCL
                 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000; 544/134.000; 544/139.000; 544/141.000; 544/143.000
        NCLS:
         [6]
IC
         ICM: C07D265-32
         ICS: C07D279-12; C07D413-04; C07D413-06; C07D413-14
         544/132; 544/134; 544/139; 544/141; 544/143; 514/235.2; 514/235.5;
EXF
         514/235.8; 514/233.5; 514/236.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
      ANSWER 92 OF 128 USPATFULL ON STN
        97:94081 USPATFULL
AN
```

protein precursor homolog and kunitz-type

\*\*\*amyloid\*\*\*

TI

Human

```
Sprecher, Cindy A., Seattle, WA, United States
ΙN
       Foster, Donald C., Seattle, WA, United States
       Norris, Kjeld E., Hellerup, Denmark
       Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)
PA
       us 5677146
                                 19971014
PΙ
                                 19950418 (8)
       us 1995-424022
ΑI
       Continuation of Ser. No. US 1993-155331, filed on 19 Nov 1993, now
RLI
       patented, Pat. No. US 5441931 And Ser. No. US 1992-985692, filed on 2
       Dec 1992, now patented, Pat. No. US 5436153
       Utility
DT
       Granted
FS
LN.CNT 1598
       INCLM: 435/069.100
INCL
       INCLS: 435/069.200; 435/252.330; 435/254.200; 435/254.210; 435/325.000
       NCLM:
               435/069.100
NCL
               435/069.200; 435/252.330; 435/254.200; 435/254.210; 435/325.000
       NCLS:
IC
       [6]
       ICM: C12N015-09
       ICS: C12N015-15; C12N015-70; C12N015-79
       435/6; 435/69.1; 435/212; 435/213; 435/240.2; 435/252.3; 435/320.1;
FXF
       435/69.2; 435/325; 435/254.2; 435/254.21; 435/252.33; 536/22.1;
       536/23.1; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 93 OF 128 USPATFULL on STN
       97:86731 USPATFULL
ΑN
       Elk ligand fusion proteins
ΤI
       Lyman, Stewart, Seattle, WA, United States
ΤN
       Beckmann, M. Patricia, Poulsbo, WA, United States
       Baum, Peter R., Seattle, WA, United States
       Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PA
                                 19970923
       us 5670625
PI
                                 19950602 (8)
       us 1995-460741
ΑI
       Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
RLI
       Pat. No. US 5512457, issued on 30 Apr 1996 which is a
       continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 1742
       INCLM: 530/387.300
INCLS: 435/069.700; 435/172.300; 424/085.100; 424/192.100; 536/023.400;
INCL
               935/010.000; 530/351.000; 930/140.000
       NCLM:
               530/387.300
NCL
               424/085.100; 424/192.100; 435/069.700; 530/351.000; 536/023.400;
       NCLS:
               930/140.000
        [6]
IC
       ICM: C07K014-52
        ICS: C07K019-00
       530/387.3; 530/351; 435/69.7; 435/172.3; 435/69.1; 435/320.1; 424/85.1; 424/192.1; 536/23.4; 536/23.5; 935/10; 930/140
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 94 OF 128 USPATFULL ON STN
L4
       97:49813 USPATFULL
ΑN
        Process for making (25,5s)-5-fluoromethylornithine
TI
        Jund, Karin, Strasbourg, France
TN
               Jean-Bernard, Sundhoffen, France
       Merrell Pharmaceuticals, Inc., Cincinnati, OH, United States (U.S.
PA
        corporation)
                                 19970610
PΙ
       us 5637768
                                                                        <--
                                                                        <--
       wo 9417795
                    19940818
       us 1995-491968
                                 19950718 (8)
ΑI
       wo 1993-US11283
                                 19931119
                                            PCT 371 date
                                 19950718
                                 19950718
                                           PCT 102(e) date
                             19930205
PRAI
       FR 1993-400303
       Utility
DT
FS
        Granted
LN.CNT 1096
INCL
        INCLM: 562/561.000
       NCLM: 562/561.000
NCL
IC
        [6]
        ICM: C07C229-00
EXF
        514/564; 562/561
```

```
ANSWER 95 OF 128 USPATFULL ON STN
L4
        97:49744 USPATFULL
ΑN
        Process for preparing morpholine tachykinin receptor antagonists
TI
        Dorn, Conrad P., Plainfield, NJ, United States
IN
        Hale, Jeffrey J., Westfield, NJ, United States
        Finke, Paul E., Milltown, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
Shah, Shrenik K., Metuchen, NJ, United States
        Chambers, Mark S., Watford Harts, England
        Harrison, Timothy, Great Dunmow, England
        Ladduwahetty, Tamara, Buckhurst Hill, England
        Williams, Brian J., Great Dunnow, England
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
US 5637699 19970610 <--
PA
        us 5637699
PΙ
        us 1995-445489
                                      19950522 (8)
ΑI
        Division of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned
RLI
        which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19
        May 1993, now abandoned which is a continuation-in-part of Ser. No. US
        1992-971448, filed on 4 Nov 1992, now abandoned which is a
        continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 6269
INCL
         INCLM: 540/524.000
         INCLS: 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000;
                 544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000;
                 544/153.000; 544/174.000
NCL
        NCLM:
                 540/524.000
                 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000; 544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000; 544/153.000; 544/174.000
        NCLS:
IC
         [6]
         ICM: C07D413-02
ANSWER 96 OF 128 USPATFULL ON STN
L4
         97:38610 USPATFULL
ΑN
         Cytokine designated elk ligand
TI
         Lyman, Stewart, Seattle, WA, United States
IN
         Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
         Immunex Corporation, Seattle, WA, United States (U.S. corporation) US 5627267 19970506 <--
PA
PI
         us 1995-458077
                                      19950601 (8)
ΑI
         Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
RLI
         Pat. No. US 5512457 which is a continuation-in-part of Ser. No. US
         1992-977693, filed on 13 Nov 1992, now abandoned
DT
         Utility
         Granted
FS
LN.CNT 1743
         INCLM: 530/351.000
INCL
         INCLS: 424/085.100; 435/069.500; 536/023.500; 935/009.000; 930/140.000
NCL
         NCLM:
                  530/351.000
                 424/085.100; 435/069.500; 536/023.500; 930/140.000
         NCLS:
         [6]
IC
         ICM: C07K014-52
         530/351; 424/85.1; 514/12; 435/69.5; 536/23.5; 935/9; 930/140
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 97 OF 128 USPATFULL ON STN
L4
         97:26904 USPATFULL
ΑN
         Non-crosslinked protein particles for therapeutic and diagnostic use
 TI
         Yen, Richard C. K., Glendora, CA, United States
Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
US 5616311 19970401
 IN
 PΑ
PΤ
                                      19940314 (8)
         us 1994-212546
ΑI
```

```
abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now
       patented, Pat. No. US 5308620 which is a continuation-in-part of Ser.
       No. US 1991-641720, filed on 15 Jan 1991, now abandoned
       Utility
DT
       Granted
FS
LN.CNT 2585
       INCLM: 424/001.330
INCL
                             424/001.370; 424/484.000; 424/499.000; 424/002.140;
        INCLS: 424/001.290;
                             424/213.300; 424/213.330; 428/402.200; 428/402.240;
               424/002.210;
               435/177.000; 935/054.000
       NCLM:
               424/001.330
NCL
               424/001.290; 424/001.370; 424/484.000; 424/499.000; 427/002.140;
       NCLS:
               427/002.210; 427/213.300; 427/213.330; 428/402.200; 428/402.240;
               435/177.000
        [6]
IC
        ICM: A61K051-08
       264/4.3; 427/213.33; 427/2; 427/2.14; 427/2.21; 427/3; 427/213.3; 428/402.2; 428/402.24; 424/1.29; 424/1.33; 424/1.37; 424/484; 424/499; 514/832; 514/965; 935/54; 435/177
        ICS: A61K009-50; B01J013-08; C12N011-02
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 98 OF 128 USPATFULL ON STN
L4
        97:22926 USPATFULL
ΑN
        Transgenic animals harboring APP allele having swedish mutation
TI
        McConlogue, Lisa C., San Francisco, CA, United States
IN
        Zhao, Jun, San Diego, CA, United States
Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
PA
        corporation)
        Eli Lilly and Company, Indianapolis, IN, United States (U.S.
        corporation)
                                   19970318
        us 5612486
PΙ
                                   19931101 (8)
        us 1993-148211
ΑI
        Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993
RLI
DT
        Utility
        Granted
FS
LN.CNT 1759
        INCLM: 800/002.000
INCL
        INCLS: 435/172.300; 536/023.500; 536/023.100
        NCLM: 800/012.000
NCL
               536/023.100; 536/023.500; 800/018.000
        NCLS:
TC
        [6]
        ICM: C12N015-00
        ICS: C07H021-04
        800/2; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 99 OF 128 USPATFULL ON STN
L4
        97:20534 USPATFULL
ΑN
        N-acylpiperidine tachykinin antagonists
TI
        MacCoss, Malcolm, Freehold, NJ, United States
IN
        Mills, Sander G., Woodbridge, NJ, United States
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
                                   19970311
PI
        us 5610165
        us 1994-198025
                                   19940217 (8)
ΑI
        Utility
DT
FS
        Granted
LN.CNT 2279
        INCLM: 514/315.000
INCL
        INCLS: 514/325.000; 546/226.000
NCL
                514/315.000
        NCI M:
        NCLS:
                514/325.000; 546/226.000
IC
        [6]
        ICM: A61K031-445
        ICS: C07D211-06
        514/315; 546/226
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 100 OF 128 USPATFULL ON STN
        97:18161 USPATFULL
AN
        Substituted aryl piperazines as neurokinin antagonists
TI
        Chiang, Yuan-Ching P., Scotch Plains, NJ, United States
IN
        Finke, Paul E., Milltown, NJ, United States Maccoss, Malcolm, Freehold, NJ, United States
        Meurer, Laura C., Scotch Plains, NJ, United States
```

```
Mills, Sander G., Woodbridge, NJ, United States
       Robichaud, Albert J., Stirling, NJ, United States
       Shah, Shrenik K., Metuchen, NJ, United States
       Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
                               19970304
PΙ
       us 5607936
                               19940930 (8)
ΑI
       us 1994-316013
       Utility
DT
       Granted
FS
LN.CNT
       2690
       INCLM: 514/255.000
INCL
       INCLS: 544/365.000; 544/366.000; 544/370.000; 544/393.000; 544/395.000
              514/253.120
NCL
       NCLM:
              514/254.050; 514/255.030; 544/365.000; 544/366.000; 544/370.000;
       NCLS:
              544/393.000; 544/395.000
IC
       [6]
       ICM: C07D403-10
       ICS: A61K031-495
       546/393; 546/370; 546/366; 546/395; 546/365; 514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 101 OF 128 USPATFULL on STN
L4
       97:15968 USPATFULL
ΑN
       Methods and compositions for monitoring cellular processing of
TI
         ***beta*** - ***amyloid***
                                       precursor protein
       Seubert, Peter A., South San Francisco, CA, United States
IN
       Schenk, Dale B., Pacifica, CA, United States
       Fritz, Lawrence C., San Francisco, CA, United States
       Athena Neurosciences, Inc., South San Francisco, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
                                19970225
PΙ
       us 5605811
       us 1995-440261
                                19950512 (8)
ΑI
       Division of Ser. No. US 1992-965971, filed on 26 Oct 1992, now patented,
RLI
       Pat. No. US 5441870 which is a continuation-in-part of Ser. No. US
       1995-868949, filed on 15 Apr 1995, now abandoned
       Utility
DT
FS
       Granted
LN.CNT 1012
       INCLM: 435/029.000
INCL
       INCLS: 435/023.000; 435/069.200; 424/009.200
       NCLM:
              435/029.000
NCL
              424/009.200; 435/023.000; 435/069.200
       NCLS:
IC
       [6]
       ICM: C12Q001-02
       435/7.4; 435/23; 435/24; 435/29; 435/41; 435/69.2; 435/184; 424/9.2
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 102 OF 128 USPATFULL ON STN
L4
       97:14579 USPATFULL
AN
       Methods of screening for . ***beta*** .- ***amyloid***
                                                                     peptide
ΤI
       production inhibitors
       McConlogue, Lisa C., San Francisco, CA, United States
IN
       Schenk, Dale B., Pacifica, CA, United States
       Seubert, Peter A., South San Francisco, CA, United States
       Sinha, Sukanto, San Francisco, CA, United States
       Zhao, Jun, La Jolla, CA, United States
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       us 5604102
                                19970218
PΙ
       US 1993-143697
                                19931027 (8)
ΑI
       Continuation-in-part of Ser. No. US 1992-965971, filed on 26 Oct 1992,
RLI
       now patented, Pat. No. US 5441870 which is a continuation-in-part of
       Ser. No. US 1992-868949, filed on 15 Apr 1992, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 1288
        INCLM: 435/007.100
INCL
       INCLS: 424/009.200; 435/007.210; 435/172.300; 800/002.000; 530/350.000
NCL
               435/007.100
       NCLM:
              424/009.200; 435/007.210; 530/350.000
       NCLS:
IC
        ICM: C12N015-00
       ICS: G01N033-53; G01N033-567; A61K049-00
EXF
       435/6: 435/7.1: 800/2: 530/350; 424/9
```

```
ANSWER 103 OF 128 USPATFULL on STN
L4
       97:3695
                USPATFULL
ΑN
       Methods for the detection of soluble . ***beta*** .- ***amyloid***
TI
       peptide
       Schenk, Dale B., Pacifica, CA, United States
IN
       Seubert, Peter A., South San Francisco, CA, United States
       Vigo-Pelfrey, Carmen, Mountain View, CA, United States
       Athena Neurosciences, South San Francisco, CA, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
       us 5593846
                                19970114
PΙ
       us 1995-437067
                                19950509 (8)
AΙ
       Continuation of Ser. No. US 1992-965972, filed on 26 Oct 1992, now
RLI
       abandoned which is a continuation-in-part of Ser. No. US 1992-911647.
       filed on 10 Jul 1992, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 1468
       INCLM: 435/007.900
INCL
       INCLS: 435/007.920; 435/007.940; 436/518.000; 436/528.000; 436/811.000
       NCLM:
              435/007.900
NCI
              435/007.920; 435/007.940; 436/518.000; 436/528.000; 436/811.000
       NCLS:
IC
       [6]
       ICM: G01N033-53
       ICS: G01N033-537; G01N033-543
       435/7.9; 435/7.92; 435/7.94; 435/967; 435/975; 436/518; 436/548; 436/811
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 104 OF 128 USPATFULL on STN
1.4
       96:120572 USPATFULL
AN
       Methods for the prevention or treatment of vascular hemorrhaging and
TI
       Alzheimer's disease
       Anderson, Stephen, Princeton, NJ, United States
IN
       Rutgers, The State University of New Jersey, Piscataway, NJ, United
PA
       States (U.S. corporation)
PΙ
       us 5589154
                                 19961231
                                                                        <--
                                 19941122 (8)
ΑI
       us 1994-347144
       Utility
DT
FS
       Granted
LN.CNT 1362
INCL
       INCLM: 424/001.410
       INCLS: 424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100;
               424/145.100; 436/543.000; 436/547.000; 435/007.100; 530/380.000
              424/001.410
       NCLM:
NCL
              424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100; 424/145.100; 435/007.100; 436/543.000; 436/547.000; 530/380.000
       NCLS:
IC
       [6]
       ICM: A61K051-00
       ICS: A61K039-395; A61K035-14; G01N033-53
       424/1.49; 424/1.69; 424/1.41; 424/9.34; 424/9.6; 424/130.1; 424/145.1;
EXF
       436/543; 436/547; 435/7.1; 530/380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 105 OF 128 USPATFULL ON STN
       96:65441 USPATFULL
ΑN
         ***Beta***
                     - ***amyloid***
                                          peptide production inhibitors and
ΤI
       methods for their identification
       Knops, Jeroen, San Francisco, CA, United States
IN
       Sinha, Sukanto, San Francisco, CA, United States
       Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
       us 5538845
                                 19960723
PΙ
                                                                        <--
       US 1992-831722
ΑI
                                 19920205 (7)
       Utility
DT
FS
       Granted
LN.CNT 825
       INCLM: 435/006.000
INCL
       INCLS: 435/007.210; 435/069.200; 435/183.000; 436/530.000; 436/531.000;
               530/387.100
               435/006.000
NCL
       NCLM:
```

435/007.210; 435/069.200; 435/183.000; 436/530.000; 436/531.000;

NCLS:

```
IC
        [6]
       ICM: G01N033-567
       ICS: G01N033-544; G01N033-545; C12Q001-68
       435/29; 435/4; 435/3; 435/69.1; 435/70.3; 435/7.21; 435/6; 435/7.92;
EXF
       435/69.2; 435/183; 435/184; 530/350; 530/361; 530/83.9; 436/518;
       436/528; 436/529; 436/530; 436/531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 106 OF 128 USPATFULL ON STN
14
       96:60705 USPATFULL
ΑN
       Spiro compounds containing five-membered rings
TI
       Fisher, Abraham, 4717 David Elazar Street, Holon, Israel
IN
       Karton, Yishai, 8 Ben-Gurion Street, Ness-Ziona, Israel
       Marciano, Daniele, 22 Usichkin Street, Ramat-Hasharon, Israel
       Barak, Dov, 20 Usichkin Street, Removot, Israel
Meshulam, Haim, 13 Harishohim Street, Bat-Yam, Israel
                                  19960709
       us 5534520
PΙ
       us 1993-94855
                                  19930720 (8)
ΑI
       Continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991,
RLI
        now abandoned which is a continuation-in-part of Ser. No. US
        1990-507708, filed on 10 Apr 1990, now abandoned
        Utility
DT
FS
        Granted
LN.CNT 2865
        INCLM: 514/278.000
INCL
               546/016.000; 546/019.000; 546/020.000
        INCLS:
               514/278.000
NCL
               546/016.000; 546/019.000; 546/020.000
        NCLS:
IC
        [6]
        ICM: A61K031-445
        ICS: C07D221-20; C07D491-10; C07D491-20 546/16; 546/19; 546/20; 514/278
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 107 OF 128 USPATFULL ON STN
L4
        96:36566 USPATFULL
AN
        Treatment of emesis with morpholine tachykinin receptor antagonists
TI
        Dorn, Conrad P., Plainfield, NJ, United States
IN
        MacCoss, Malcolm, Freehold, NJ, United States
        Hale, Jeffrey J., Westfield, NJ, United States
        Mills, Sander G., Woodbridge, NJ, United States
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PA
                                  19960430
PΙ
        us 5512570
        us 1995-450507
                                  19950525 (8)
ΑI
        Division of Ser. No. US 1994-206771, filed on 4 Mar 1994
RLI
DT
        Utility
FS
        Granted
LN.CNT 6501
        INCLM: 514/236.200
INCL
               514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200
        INCLS:
                514/236.200
NCL
        NCLM:
               514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200
        NCLS:
        [6]
IC
        ICM: A61K031-535
        ICS: C07D413-00
        514/235.8; 514/236.5; 514/236.2; 514/236.8; 514/235.5; 514/237.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 108 OF 128 USPATFULL ON STN
        96:36458 USPATFULL
ΑN
        Cytokine designated elk ligand
TI
        Lyman, Stewart, Seattle, WA, United States
IN
        Beckmann, M. Patricia, Poulsbo, WA, United States
        Baum, Peter R., Seattle, WA, United States
Carpenter, Melissa K., Issaquah, WA, United States
        Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PA
                                  19960430
        us 5512457
PI
        us 1994-213403
                                  19940315 (8)
ΑI
        Continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT 1746
        INCLM: 435/069.500
INCL
        INCLS: 435/172.100; 435/320.100; 424/085.100; 536/023.500; 536/024.310;
```

```
435/069.500
        NCLM:
NCL
                424/085.100; 435/320.100; 530/351.000; 536/023.500; 536/024.310;
        NCLS:
                930/140.000
        [6]
IC
        ICM: C07H021-04
        ICS: C12P021-02; C12N015-19; C07K014-52
        536/23.5; 536/24.5; 536/24.31; 530/350; 530/351; 435/69.1; 435/320.1; 435/172.1; 935/9; 424/85.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 109 OF 128 USPATFULL ON STN
L4
        96:29585 USPATFULL
ΑN
        Proline derivatives possessing prolyl endopeptidase-inhibitory activity
TI
        Kobayashi, Koji, Kasugai, Japan
IN
        Nishii, Kazuhiko, Takatsuki, Japan
        Iwata, Kunio, Takatsuki, Japan
Uchida, Itsuo, Takatsuki, Japan
Yoshitomi Pharmaceutical Industries, Ltd., both of, Japan (non-U.S.
PA
        corporation)
        Japan Tobacco Inc., both of, Japan (non-U.S. corporation)
                                                                              <--
                                    19960409
PΙ
        us 5506256
                                    19930226 (8)
        US 1993-26311
ΑI
        Continuation-in-part of Ser. No. US 1992-883116, filed on 14 May 1992, now abandoned which is a continuation-in-part of Ser. No. US
RLI
        1991-734692, filed on 23 Jul 1991, now abandoned
                               19900727
PRAI
        JP 1990-197835
        JP 1990-418334
                               19901227
        JP 1991-361355
                               19911227
DT
        Utility
        Granted
FS
LN.CNT 3020
        INCLM: 514/422.000
INCL
        INCLS: 548/518.000; 548/524.000
                514/422.000
NCL
        NCLM:
                548/518.000; 548/524.000
        NCLS:
        [6]
IC
        ICM: A61K031-40
        ICS: C07D403-06; C07D403-14
        514/422; 548/524; 548/518
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 110 OF 128 USPATFULL ON STN
L4
        96:14713 USPATFULL
ΑN
        Diagnostic method for Alzheimer's disease by screening for tau-peptides
ΤI
        in the blood of a patient
        Vooheis, H. Paul, Dublin, Ireland
IN
        Provost, Fellows and Scholars of Trinity College, Dublin, Ireland
PA
        (non-U.S. corporation)
        US 5492812
US 1993-159969
                                    19960220
PΙ
                                    19931130 (8)
ΑI
        Continuation of Ser. No. US 1991-738778, filed on 1 Aug 1991, now
RLI
        abandoned
        Utility
DT
FS
        Granted
LN.CNT 1170
        INCLM: 435/007.100
INCL
        INCLS: 435/007.920; 435/007.930; 435/007.940; 435/007.950; 436/518.000; 436/804.000; 436/811.000
        NCLM:
                435/007.100
NCL
                435/007.920; 435/007.930; 435/007.940; 435/007.950; 436/518.000;
        NCLS:
                436/804.000; 436/811.000
        [6]
IC
        ICM: G01N033-53
        ICS: G01N033-537; G01N033-543
        435/7.1; 435/7.2; 435/7.21; 435/7.92; 435/975; 436/506; 436/518; 436/512; 436/811; 436/864; 436/828; 436/515; 436/516; 436/808
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 111 OF 128 USPATFULL ON STN
L4
        95:88552 USPATFULL
AN
        DNA encoding novel human kunitz-type inhibitors and methods relating
TI
        Sprecher, Cindy A., Seattle, WA, United States
IN
        Kisiel, Walt, Albuquerque, NM, United States
         Foster, Donald C., Seattle, WA, United States
```

```
University of New Mexico, Albuquerque, NM, United States (U.S.
        corporation)
                                                                               <--
        us 5455338
                                    19951003
PΙ
                                    19931105 (8)
        us 1993-147710
ΑI
        Utility
DT
FS
        Granted
LN.CNT 1658
        INCLM: 536/023.500
INCL
        INCLS: 435/006.000; 435/091.100; 435/069.600; 435/252.330; 435/069.100;
                530/350.000; 530/381.000; 530/384.000
                536/023.500
        NCLM:
NCL
                435/006.000; 435/069.100; 435/069.600; 435/091.100; 435/252.330;
        NCLS:
                530/350.000; 530/381.000; 530/384.000
        [6]
IC
        ICM: C12N015-15
        ICS: C12N015-64
        530/350; 530/381; 530/384; 536/23.5; 435/6; 435/91.1; 435/69.6; 435/252.33
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 112 OF 128 USPATFULL ON STN
L4
        95:88386 USPATFULL
ΑN
        Nucleic acids for diagnosing and modeling Alzheimer's disease
TI
        Mullan, Michael J., Tampa, FL, United States
IN
        Alzheimer's Institute of America, Inc., Prairie Village, KS, United
PA
        States (U.S. corporation)
        us 5455169
                                    19951003
                                                                               <--
PΙ
        us 1992-894211
                                    19920604 (7)
ΑI
DT
        Utility
        Granted
FS
LN.CNT 1040
INCL
        INCLM: 435/240.200
        INCLS: 435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330
                435/325.000
NCL
        NCLM:
                435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330
        NCLS:
IC
        [6]
        ICM: C12N005-10
        ICS: C12N015-12: C12N015-85
        435/240.2; 435/320.1; 435/172.3; 435/6; 536/23.1; 536/23.5; 536/24.31;
EXF
        536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 113 OF 128 USPATFULL on STN
L4
        95:73612 USPATFULL
Human ***amyloid***
ΑN
                                    protein precursor homologue and Kunitz-type
TI
        inhibitors
        Sprecher, Cindy A., 8206 39th Ave. NE., Seattle, WA, United States
IN
        98115
        Foster, Donald C., 3002 NE. 181st St., Seattle, WA, United States 98115
        Norris, Kjeld E., Ahlmanns Alle 34, 2900 Hellerup, Denmark US 5441931 19950815
PΙ
        US 1993-155331
                                    19931119 (8)
ΑI
        Continuation-in-part of Ser. No. US 1992-985692, filed on 2 Dec 1992
RLI
DT
        Utility
        Granted
FS
LN.CNT 1559
INCL
        INCLM: 514/002.000
        INCLS: 435/069.100; 435/069.200; 435/212.000; 435/213.000; 435/252.300; 435/240.200; 435/320.100; 530/350.000; 536/022.100; 536/023.100; 536/023.500
                 514/002.000
NCL
        NCLM:
                435/069.100; 435/069.200; 435/212.000; 435/213.000; 435/252.300; 435/320.100; 530/350.000; 536/022.100; 536/023.100; 536/023.200;
        NCLS:
                 536/023.500
         [6]
IC
         ICM: A61K038-00
        ICS: C07K001-00; C12N001-20; C12P021-06 435/69.1; 435/69.2; 435/212; 435/213; 435/252.3; 435/320.1; 435/240.2; 536/27.1; 536/23.1; 536/23.2; 536/23.5; 530/350; 514/2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 114 OF 128 USPATFULL on STN
L4
        95:73552 USPATFULL
AN
        Methods for monitoring cellular processing of . ***beta***
TI
```

\*\*\*amyloid\*\*\*

precursor protein

```
schenk, Dale B., Pacifica, CA, United States
       Fritz, Lawrence C., San Francisco, CA, United States
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
       us 5441870
                                  19950815
PΙ
       us 1992-965971
                                  19921026 (7)
ΑI
       Continuation-in-part of Ser. No. US 1992-868949, filed on 15 Apr 1992,
RLI
       now abandoned
       Utility
DT
       Granted
FS
LN.CNT 1030
       INCLM: 435/007.100
INCL
       INCLS: 435/007.920; 435/007.210; 436/518.000; 436/811.000
               435/007.100
NCL
               435/007.210; 435/007.920; 436/518.000; 436/811.000
       NCLS:
        [6]
IC
       ICM: G01N033-53
       435/7.1; 435/7.4; 435/7.92; 435/7.21; 435/41; 436/518; 436/547; 436/548;
EXF
        436/63; 436/804; 436/811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 115 OF 128 USPATFULL ON STN
L4
       95:67145 USPATFULL
Human ***amyloid***
ΑN
                                  protein precursor homolog and Kunitz-type
TI
        inhibitor
        Sprecher, Cindy A., 8207 - 39th Ave., NE., Seattle, WA, United States
IN
        98115
        Foster, Donald C., 3002 NE. 181st St., Seattle, WA, United States
        Norris, Kjeld E., Ahlmanns Alle 34, 2900 Hellerup, Denmark
                                  19950725
        us 5436153
PΙ
        us 1992-985692
                                  19921202 (7)
ΑĨ
        Utility
DT
        Granted
FS
LN.CNT
       1128
        INCLM: 435/240.200
INCL
        INCLS: 435/006.000; 435/069.100; 435/212.000; 435/213.000; 435/252.300;
                435/320.100; 536/022.100; 536/023.100; 536/023.200; 536/023.500
               435/252.330
        NCLM:
NCL
               435/006.000; 435/069.100; 435/212.000; 435/213.000; 435/252.300; 435/320.100; 536/022.100; 536/023.100; 536/023.200; 536/023.500
        NCLS:
        [6]
IC
        ICM: C12N005-00
        ICS: C12N009-48; C12P021-06; C07H019-00
        435/6; 435/69.1; 435/212; 435/213; 435/252.3; 435/320.1; 435/240.2;
EXF
        536/22.1; 536/23.1; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 116 OF 128 USPATFULL ON STN
L4
        95:64928 USPATFULL
ΑN
        Spiro-substituted azacycles as neurokinin-3 antagonists
TI
        Shah, Shrenik K., Metuchen, NJ, United States
ΙN
        Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
US 5434158 19950718 <-
PA
        us 5434158
PΙ
        us 1994-233487
                                  19940426 (8)
ΑI
        Utility
DT
        Granted
FS
LN.CNT 1318
        INCLM: 514/278.000
INCL
                514/252.000; 514/255.000; 514/329.000; 514/331.000; 544/360.000;
        INCLS:
                544/400.000; 546/016.000; 546/017.000; 546/223.000; 546/233.000
NCL
        NCLM:
                514/278.000
                514/255.050; 514/329.000; 514/331.000; 544/360.000; 544/400.000; 546/016.000; 546/017.000; 546/223.000; 546/233.000
        NCLS:
IC
        [6]
        ICM: A61K031-44
        ICS: A61K031-495; C07D221-00; C07D401-00
        546/16; 546/17; 514/278
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 117 OF 128 USPATFULL ON STN
L4
        95:52252 USPATFULL
ΑN
        Amyloidin protease and uses thereof
TI
        Dovev. Harry F.. Pacifica, CA, United States
```

IN

```
Sinha, Sukanto, San Francisco, CA, United States
              Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S.
PA
               corporation)
               Eli Lilly and Company, Indianapolis, IN, United States (U.S.
               corporation)
               us 5424205
                                                                   19950613
PI
                                                                   19930507 (8)
               us 1993-59032
ΑI
               Division of Ser. No. US 1991-766351, filed on 30 Sep 1991, now patented, Pat. No. US 5292652 which is a continuation-in-part of Ser. No. US
RLI
               1990-594122, filed on 5 Oct 1990, now abandoned
               Utility
DT
               Granted
FS
LN.CNT 1528
               INCLM: 435/226.000
INCL
               INCLS: 435/219.000
                              435/226.000
               NCLM:
NCL
                             435/219.000
               NCLS:
IC
                [6]
               ICM: C12N009-64
               435/226; 435/219
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
           ANSWER 118 OF 128 USPATFULL ON STN
L4
                95:11757 USPATFULL
ΑN
                                                                                   ***amyloid*** -forming pathology of
               Transgenic mice displaying the
TI
                alzheimer's disease
                Cordell, Barbara, Palo Alto, CA, United States
IN
                Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
 PA
                                                                   19950207
 PΙ
               us 5387742
                                                                   19910617 (7)
                us 1991-716725
AT
                Continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,
RLI
                now abandoned
                Utility
DT
FS
                Granted
 LN.CNT 2014
                INCLM: 800/002.000
 INCL
                INCLS: 424/009.000; 435/142.300; 536/023.500
                               800/012.000
 NCL
                NCLM:
                              536/023.500; 800/018.000
                NCLS:
 IC
                [6]
                ICM: A61K049-00
                ICS: C12N015-00; C07H015-12
800/2; 435/6; 514/44
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
           ANSWER 119 OF 128 USPATFULL ON STN
 L4
                94:77716 USPATFULL
 AN
                N.N-diacylpiperazine tachykinin antagonists
 TI
                Mills, Sander G., Woodbridge, NJ, United States
 IN
                Budhu, Richard J., Monmouth Junction, NJ, United States Dorn, Conrad P., Plainfield, NJ, United States Greenlee, William J., Teaneck, NJ, United States
                MacCoss, Malcolm, Freehold, NJ, United States
                Wu, Mu T., Clark, NJ, United States
                Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PA
                                                                    19940906
                us 5344830
 PΙ
                us 1992-988514
                                                                    19921210 (7)
 ΑI
                Utility
 DT
                Granted
 FS
 LN.CNT 2678
                 INCLM: 514/235.800
 INCL
                INCLS: 514/227.800; 514/228.200; 514/232.500; 514/253.000; 514/255.000; 514/252.000; 544/060.000; 544/121.000; 544/357.000; 544/360.000; 544/360.000; 544/360.000; 544/360.000; 544/360.000; 544/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000; 554/360.000
                                514/235.800
514/227.800; 514/228.200; 514/232.500; 514/253.130; 514/255.010;
                NCLM:
 NCL
                NCLS:
                                544/060.000; 544/121.000; 544/336.000; 544/357.000; 544/360.000; 544/361.000; 544/372.000; 544/387.000; 544/388.000; 544/390.000; 558/390.000; 560/025.000; 560/157.000
 IC
                 ICM: A61K031-495
                ICS: C07D241-04; C07D401-12; C07D413-12
544/387; 544/388; 544/360; 544/60; 544/121; 544/357; 544/372; 544/361;
 EXF
                 514/227.8: 514/228.2: 514/232.5; 514/235.8; 514/252; 514/253; 514/255
```

```
L4
     ANSWER 120 OF 128 USPATFULL ON STN
       94:20087 USPATFULL
AN
       Amyloidin protease and uses thereof
TI
       Dovey, Harry F., Pacifica, CA, United States
IN
       Seubert, Peter A., San Mateo, CA, United States
       Sinha, Sukanto, San Francisco, CA, United States
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
                                19940308
                                                                        <--
       us 5292652
PΙ
                                19910930 (7)
       us 1991-766351
ΑÏ
       Continuation-in-part of Ser. No. US 1990-594122, filed on 5 Oct 1990,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 1462
       INCLM: 435/226.000
INCL
       INCLS: 435/219.000
NCL
       NCLM:
              435/226.000
              435/219.000
       NCLS:
       [5]
IC
       ICM: C12N009-64
       435/219; 435/226; 435/23
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 121 OF 128 USPATFULL ON STN
14
       93:96052 USPATFULL
ΑN
       Diagnostic method for Alzheimer's disease: examination of non-neural
TI
       tissue
       Selkoe, Dennis J., Jamaica Plain, MA, United States
Brigham and Women's Hospital, Boston, MA, United States (U.S.
IN
PA
       corporation)
PΙ
       us 5262332
                                 19931116
                                 19890919 (7)
       US 1989-410138
AΤ
       Continuation-in-part of Ser. No. US 1989-333609, filed on 5 Apr 1989,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT
       1401
       INCLM: 436/518.000
INCL
        INCLS: 435/007.100; 435/007.900; 435/960.000; 435/967.000; 436/501.000;
               436/547.000; 436/548.000; 436/063.000; 436/174.000; 436/811.000
NCL
               436/518.000
               435/007.100; 435/007.900; 435/167.000; 435/960.000; 436/063.000;
       NCLS:
               436/174.000; 436/501.000; 436/547.000; 436/548.000; 436/811.000
IC
        [5]
        ICM: G01N033-53
        ICS: G01N033-543
        436/501; 436/518; 436/536; 436/547; 436/548; 436/63; 436/177; 436/808;
EXF
        436/811; 436/164; 530/387; 530/388.1; 530/389.1; 435/7.9; 435/7.1;
        435/960; 435/967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 122 OF 128 USPATFULL on STN
        93:65286 USPATFULL
AN
       Diagnostic assay for alzheimer's disease
TI
        Card, John P., Wilmington, DE, United States
ΙN
        Davis, Leonard G., Newark, DE, United States
        Siman, Robert G., Wilmington, DE, United States
        Du Pont Merck Pharmaceutical Company, Wilmington, DE, United States
PA
        (U.S. corporation)
       us 5234814
                                 19930810
                                                                        <--
PΙ
        US 1989-359822
                                 19890601 (7)
ΑI
        Utility
DT
        Granted
FS
LN.CNT 639
        INCLM: 435/007.210
INCL
        INCLS: 435/007.920; 436/516.000; 530/350.000; 530/395.000
        NCLM:
              435/007.210
NCL
              435/007.920; 436/516.000; 530/350.000; 530/395.000
        NCLS:
IC
        [5]
        ICM: G01N033-543
        ICS: G01N033-561; C07K013-00; C07K003-26
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 123 OF 128 USPATFULL ON STN
L4
        ΑN
                                                      peptide
TI
         Majocha, Ron, Wayland, MA, United States
IN
         Marotta, Charles A., Cambridge, MA, United States
         Zain, Sayeeda, Pittsford, NY, United States
The McLean Hospital, Belmont, MA, United States (U.S. corporation)
PA
         University of Rochester, Rochester, NY, United States (U.S. corporation)
                                        19930727
         us 5231000
PΙ
                                        19910722 (7)
         us 1991-733375
ΑI
         Continuation of Ser. No. US 1987-105751, filed on 8 Oct 1987
RLI
         Utility
DT
         Granted
FS
LN.CNT 687
         INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/240.270; 530/388.100; 436/501.000;
INCL
                  436/506.000
                  435/007.100
NCL
         NCLM:
                  435/007.200; 435/007.210; 435/331.000; 436/501.000; 436/506.000;
         NCLS:
                  530/388.100
         ۲51
IC
         ICM: G01N033-53
         ICS: G01N033-564; G01N033-577; C12N005-20 530/387; 435/240.27; 435/7.1; 435/960; 435/7.2; 435/388.2; 436/518; 436/529-530; 436/548; 436/512; 436/501; 436/507; 424/85.8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 124 OF 128 USPATFULL ON STN
L4
         93:52560 USPATFULL
AN
         Recombinant Alzheimer's protease inhibitory
                                                                    ***amyloid***
                                                                                         protein
TI
         and method of use
         Schilling, Jr., James W., Palo Alto, CA, United States Ponte, Phyllis A., Mountain View, CA, United States Cordell, Barbara, Palo Alto, CA, United States
IN
         Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
PA
                                        19930629
         us 5223482
PΙ
                                         19890606 (7)
         us 1989-361912
ΑI
         Continuation-in-part of Ser. No. US 1989-359911, filed on 12 May 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-87002,
RLI
         filed on 18 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-8810, filed on 30 Jan 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-948376, filed on 31 Dec 1986, now abandoned which is a continuation-in-part of Ser. No. US
          1986-932193, filed on 17 Nov 1986, now abandoned
DT
         Utility
FS
          Granted
LN.CNT 1757
          INCLM: 514/012.000
INCL
                   530/324.000; 530/839.000; 530/350.000; 435/069.200
          INCLS:
NCL
                   514/012.000
                  435/069.200; 435/910.000; 530/324.000; 530/350.000; 530/839.000
          NCLS:
          [5]
IC
          ICM: A61K037-64
          ICS: C07K007-10
          530/350; 530/324; 530/839; 514/12; 435/69.2
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 125 OF 128 USPATFULL ON STN
L4
          93:50478 USPATFULL
ΑN
                                           ***amyloid***
                                                                deposition
          Assays and reagents for
TI
          Cordell, Barbara, Palo Alto, CA, United States
TN
          Wolf, David, Palo Alto, CA, United States
          Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
PA
                                         19930622
PΙ
          us 5221607
ΑI
          us 1991-785142
                                         19911029 (7)
          Continuation of Ser. No. US 1989-408767, filed on 18 Sep 1989, now
RLI
          abandoned
DT
          Utility
          Granted
 LN.CNT 836
          INCLM: 435/006.000
INCL
          INCLS: 435/007.210; 435/070.100; 435/070.300; 435/172.100; 435/240.100; 435/240.200: 435/320.100; 436/811.000; 536/023.500; 530/330.000;
```

```
435/006.000
NCL
       NCLM:
               435/007.210; 435/070.100; 435/070.300; 435/320.100; 436/811.000;
       NCLS:
                530/300.000; 530/350.000; 530/806.000; 530/839.000; 536/023.500
IC
       ICM: C12Q001-68
       ICS: C07K013-00; C12N015-00 435/6; 435/70.1; 435/172.3; 435/810; 435/7.21; 435/70.3; 435/172.1;
EXF
        435/240.1; 435/240.2; 435/320.1; 436/543; 436/548; 436/808; 436/811;
        530/300; 530/350; 530/387; 530/806; 530/808; 530/810; 530/839; 536/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 126 OF 128 USPATFULL on STN
L4
        93:48672 USPATFULL
AN
        DNA sequence useful for the detection of Alzheimer's disease
ΤI
       Ponte, Phyllis A., Mountain View, CA, United States
Cordell, Barbara, Palo Alto, CA, United States
Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
IN
PA
                                   19930615
        US 5220013
PΙ
        US 1989-444118
                                   19891130 (7)
ΑI
        Continuation-in-part of Ser. No. US 1987-87002, filed on 18 Aug 1987
RLI
        now abandoned which is a continuation-in-part of Ser. No. US 1987-8810,
        filed on 30 Jan 1987, now abandoned which is a continuation-in-part of
        Ser. No. US 1986-948376, filed on 31 Dec 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-932193, filed on 17 Nov 1986,
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1417
INCL
        INCLM: 536/023.500
        INCLS: 435/006.000; 436/811.000; 530/324.000; 935/011.000; 536/024.310
                536/023.500
NCL
                435/006.000; 436/084.000; 530/324.000; 536/024.310
        NCLS:
IC
        [5]
        ICM: C08B001-04
        435/172.3; 435/320.1; 435/6; 935/11; 935/77; 935/78; 436/811; 536/27;
EXF
        530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 127 OF 128 USPATFULL ON STN
L4
        93:12511 USPATFULL
AN
                                                      ***amyloid***
                                                                        polypeptide
TI
        Methods of treatment using Alzheimer's
        derivatives
        Cordell, Barbara, Palo Alto, CA, United States
IN
        Schilling, James W., Palo Alto, CA, United States
        Katunuma, Nobuhiko, Tokushima, Japan
        Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
PA
                                   19930216
PΙ
        us 5187153
        US 1990-502273 19900329 (7)
Continuation-in-part of Ser. No. US 1989-361912, filed on 6 Jun 1989 which is a continuation of Ser. No. US 1989-359911, filed on 12 May
ΑI
RLI
        1989, now abandoned which is a continuation-in-part of Ser. No. US
        1987-87002, filed on 18 Aug 1987, now abandoned which is a
        continuation-in-part of Ser. No. US 1987-8810, filed on 30 Jan 1987, now
        abandoned which is a continuation-in-part of Ser. No. US 1986-948376,
        filed on 31 Dec 1986, now abandoned which is a continuation-in-part of
        Ser. No. US 1986-932193, filed on 17 Nov 1986, now abandoned
DT
        Utility
FS
        Granted
LN.CNT
       1918
INCL
        INCLM: 514/012.000
        INCLS: 530/324.000; 930/250.000; 514/002.000; 424/094.640
NCL
                514/012.000
                424/094.640; 514/002.000; 530/324.000; 930/250.000
        NCLS:
IC
        [5]
        ICM: A61K037-64
        514/12; 530/324; 435/69.7; 900/250
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 128 OF 128 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
L4
      1998-323377 [29]
                           WPIDS
ΑN
                           DNC C1998-099545
      N1998-252835
DNN
      New compound of dye molecule and compound binding to
                                                                    ***beta***
TT
        ***amyloid*** - where binding compound is a bio-molecule, dye and/or
      hydrophilic component, useful in in vivo diagnosis of neuro-degenerative
```

disease.

```
DYRKS, T; LICHA, K; RIEFKE, B; SEMMLER, W; TURNER, J
IN
       (UYBE-N) UNIV BERLIN INST DIAGNOSTIKFORSCHUNG; (DIAG-N) INST
PA
      DIAGNOSTIKFORSCHUNG GMBH; (SCHD) SCHERING AG
CYC
                         A1 19980528 (199829)*
A2 19980528 (199829) DE
                                                                      C09B023-02
      DE 19649971
                                                             18p
PΙ
                                                                      A61K049-00
                                                                                            <--
      wo 9822146
          RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
           W: AU CA CN HU JP KR NO US
                                                                      A61K049-00
                         A 19980610 (199843)
      AU 9872985
                         A2 19990922 (199943) DE
                                                                      A61K049-00
      EP 942756
            R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
                                                                       A61K049-00
                        A 19991208 (200016)
       CN 1237911
       JP 2001506591 W 20010522 (200134)
                                                              39p
                                                                       C07D209-14
                         B1 20011211 (200204)
                                                                       G01N033-51
       us 6329531
      DE 19649971 A1 DE 1996-19649971 19961119; WO 9822146 A2 WO 1997-DE2559 19971029; AU 9872985 A AU 1998-72985 19971029; EP 942756 A2 EP 1997-948710 19971029, WO 1997-DE2559 19971029; CN 1237911 A CN 1997-199895 19971029;
       JP 2001506591 W WO 1997-DE2559 19971029, JP 1998-523059 19971029; US
       6329531 B1 WO 1997-DE2559 19971029, US 1999-308177 19991118
      AU 9872985 A Based on WO 9822146; EP 942756 A2 Based on WO 9822146; JP
       2001506591 W Based on WO 9822146; US 6329531 B1 Based on WO 9822146
PRAI DE 1996-19649971 19961119
      ICM A61K049-00; C07D209-14; C09B023-02; G01N033-51
ICS C07D231-22; C07D277-60; C07D277-64; C07H005-06; C07H013-08;
C07K014-00; C07K016-00; C08B037-00; C09B056-16; C09B057-04;
C09B069-10; G01N021-64; G01N033-48; G01N033-53; G01N033-533;
G01N033-58; G01N035-533
STN INTERNATIONAL LOGOFF AT 15:25:25 ON 09 FEB 2004
```